Podcasts about CRISPR

Allora ciccini e ciccine, oggi scendiamo talmente in piccolo che manco con la lente di Sherlock Holmes vedete qualcosa

As the popularity of online prediction markets grows, correspondent Anderson Cooper sits down with Polymarket founder and CEO Shayne Coplan in his first network television interview. The 27-year-old newly minted billionaire talks about his platform, where users can bet on politics and pop culture, sports and finance, even war and peace, and how all that data can be used to forecast the future. After a three-year U.S. ban, Coplan explains how Polymarket works, and how the company finds itself poised to reenter the U.S. market with backing from Washington, Wall Street and Silicon Valley.  America's next wave of scientific talent may come from Lambert High School, where students used CRISPR to develop a promising new way to detect and treat Lyme disease, which affects nearly half a million Americans each year. Correspondent Bill Whitaker meets these “CRISPR kids” as they take their breakthrough to iGEM—the global biotech Olympics in Paris—and face off against the world's new rising force in biotechnology: China.  Barcelona's 18-year-old soccer phenom Lamine Yamal has captivated fans with his improvisation and flair. Already, he is considered a generational talent and an heir to the great Lionel Messi. Correspondent Jon Wertheim meets Lamine Yamal in his home country of Spain to talk about his rapid ascent ahead of next summer's World Cup in North America. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

CRISPR-based gene editing has revolutionized modern biology, but these tools are unable to access the DNA that resides inside mitochondria. Researchers are eager to access and edit this DNA to understand more about the energy production and the mutations that can cause incurable mitochondrial diseases.Because CRISPR can't help with these problems, researchers have been looking for other ways to precisely edit the mitochrondrial genome. And the past few years have brought some success — if researchers can make editing safe and accurate enough, it could eventually be used to treat, and even cure, these genetic conditions.This is an audio version of our Feature: Faulty mitochondria cause deadly diseases — fixing them is about to get a lot easier Hosted on Acast. See acast.com/privacy for more information.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some of the most significant and exciting advancements shaping the industry.Let's start with a breakthrough coming out of recent clinical trials. A novel approach to treating Alzheimer's disease is making waves. Researchers have been focusing on a monoclonal antibody designed to target amyloid-beta plaques in the brains of patients suffering from this debilitating condition. The latest Phase 3 trial results have shown a promising reduction in cognitive decline among participants, offering a glimmer of hope for millions affected by Alzheimer's worldwide. The study, conducted over 18 months, involved more than 1,500 patients and demonstrated a statistically significant slowing of disease progression compared to placebo. This could mark a pivotal moment in Alzheimer's treatment, shifting the paradigm from symptomatic relief to disease modification.In regulatory news, the FDA has granted approval to a new gene therapy for hemophilia B. This therapy, developed using cutting-edge CRISPR technology, offers a potential cure for patients who have long relied on regular infusions to manage their bleeding disorder. By directly editing the genes responsible for clotting factor production, this therapy can potentially provide long-term relief with just a single administration. The approval follows extensive clinical trials that showed sustained increases in clotting factor levels and a dramatic reduction in bleeding episodes among participants. This development not only underscores the growing impact of genomic medicine but also highlights the regulatory body's commitment to advancing innovative treatments that meet unmet medical needs.Shifting focus, there's an intriguing trend emerging in oncology drug development. The industry is increasingly adopting personalized medicine approaches, tailoring treatments based on individual genetic profiles. This shift is particularly evident in the rise of targeted therapies and combination regimens designed to tackle cancer at its genetic roots. A recent study demonstrated how combining targeted therapies with immune checkpoint inhibitors can enhance treatment efficacy in certain types of cancer, such as melanoma and non-small cell lung cancer. By understanding the specific mutations driving tumor growth and leveraging the body's immune response, these combinations are setting new standards for cancer care.In another significant development, researchers have unveiled promising results from an innovative mRNA vaccine trial aimed at combating infectious diseases beyond COVID-19. The technology, which gained prominence during the pandemic, is now being applied to other viral threats like influenza and RSV. Early-phase clinical trials have shown robust immune responses and favorable safety profiles, suggesting mRNA vaccines could soon revolutionize how we approach vaccination for a variety of pathogens. This versatility and rapid development timeline make mRNA platforms particularly attractive for addressing emerging infectious diseases swiftly.Meanwhile, a new study has raised awareness about antibiotic resistance—a growing concern globally. Scientists have developed an advanced diagnostic tool capable of rapidly identifying bacterial infections and their resistance profiles within hours instead of days. This innovation can significantly impact how clinicians prescribe antibiotics, ensuring targeted treatments that minimize resistance development. By providing real-time insights into bacterial genetics and resistance mechanisms, this tool empowers healthcare providers to make informed decisions that preserve antibiotic efficacy for future generations.Lastly, let's toSupport the show

Welcome back to the Information Entropy Podcast! In this episode, we break down the building blocks of life, from atoms and molecules to DNA and RNA. We then dive into the world of genetic engineering, exploring what CRISPR is, how it works, and why it's become one of the most important tools in modern biology and why scientists are so eager to rewrite genetic code. This week is Part 1 where we set the stage and foundational knowledge, next week we will explore the possible exploitations of such a technology… good and bad! Music: HOME – AWAY

This is one in a series about possible futures, which will be published in Booch News over the coming weeks. Episode 7 appeared last week. New episodes drop every Friday. Overview Peer-to-peer flavor-sharing platforms enabled home brewers to distribute taste profiles as digital files. Blockchain-verified SCOBY genetics allowed anyone to recreate award-winning kombucha flavors. Traditional beverage companies lost control as open-source fermentation recipes spread globally. This episode follows teenage hacker Luna Reyes as she reverse-engineers Heineken’s proprietary “A-yeast” strain and the century-old master strain used for Budweiser, releasing them under Creative Commons license, triggering a flavor renaissance that made corporate beverages taste like cardboard by comparison. Luna Reyes: The Seventeen-Year-Old Who Liberated Flavor Luna Reyes was brewing kombucha in her Oakland garage when she changed the course of human history. The daughter of Mexican immigrants, she had learned fermentation from her grandmother while teaching herself bioinformatics through YouTube tutorials and volunteering at the Counter Culture Labs Maker Space on Shattuck Avenue. By fifteen, she was running the Bay Area’s most sophisticated home laboratory, utilizing jury-rigged DNA sequencers and microscopes constructed from smartphone cameras. Her breakthrough came in February 2043 while investigating why her kombucha never tasted quite like expensive craft varieties and was different again from her grandmother’s home brew. Using Crispr techniques learned from online forums, Luna began reverse-engineering the microbial genetics of premium alcoholic beverages. Her target wasn’t kombucha—it was the closely guarded yeast strains that gave corporate beers their distinctive flavors. Luna hunched over her microscope, examining bacterial cultures from her latest kombucha batch. Around her, salvaged DNA sequencers hummed, fermentation vessels bubbled, and computer screens displayed multi-hued patterns of genetic sequences. Her grandmother, Rosa, entered carrying a tray with three glasses of homemade kombucha. “Mija, you’ve been working for six hours straight. Drink something.” Luna accepted the glass without looking up. “Abuela, your kombucha tastes better than anything I can buy in stores and the ones I’ve experimented with. Why? I’m using the same base ingredients—tea, sugar, water—but mine never has this complexity.” Her grandmother laughed. “Because I’ve been feeding this SCOBY for forty years. It knows what to do. You can’t rush relationships.” Luna’s sister Maya, lounging against a workbench, waved her phone. “Luna, people have noticed your forum post about Health-Ade’s fermentation process. Someone says you’re wasting your time trying to replicate commercial kombuchas.” “I’m not trying to replicate them,” Luna said, finally looking up. “I’m trying to understand why their kombucha tastes different than that I make at home. It’s not the ingredients. It’s not the process. It’s the microbial genetics.” Rosa sat down beside her granddaughter. “When I was young in Oaxaca, every family had their own kombucha culture, passed down generation to generation. Each tasted different because the bacteria adapted to their environment, their ingredients, their care. We had a saying, Hay tantas fermentaciones en el mundo como estrellas en el cielo nocturno – there are as many ferments in the world as stars in the night sky. The big companies want every bottle to be identical. That kills what makes fermentation special.” “Exactly!” Luna pulled up genetic sequences on her screen. “I’ve been reverse-engineering samples from different commercial kombuchas. Health-Ade, GT’s, Brew Dr—they all have consistent microbial profiles.” The Great Heist: Cracking Corporate DNA Luna’s first major hack targeted Heineken’s legendary “A-yeast” strain, developed in 1886 by Dr. Hartog Elion—a student of renowned chemist Louis Pasteur—in the company’s Amsterdam laboratory and protected by over 150 years of trade secret law. Using samples obtained from discarded brewery waste (technically legal under the “garbage doctrine”), she spent six months mapping the strain’s complete genetic sequence in her makeshift lab. The breakthrough required extraordinary ingenuity. Luna couldn’t afford professional gene sequencers, so she modified a broken Illumina iSeq100 purchased on eBay for $200. Her sequencing runs took weeks rather than hours; her results were identical to those produced by million-dollar laboratory equipment. Her detailed laboratory notebooks, later published as The Garage Genomics Manifesto, became essential reading for the biotech hacker movement. The Budweiser project proved even more challenging. Anheuser-Busch’s century-old master strain had been protected by layers of corporate secrecy rivaling classified military programs. The company maintained multiple backup cultures in cryogenic facilities across three continents, never allowing complete genetic mapping by outside researchers. Luna’s success required infiltrating the company’s waste-disposal systems at four breweries, collecting samples over 18 months while evading corporate security. The Decision The night before Luna was scheduled to meet her fellow bio-hackers at Oakland’s Counter Culture Labs, she sat at her workstation, hesitant, wondering if she was doing the right thing. Her sister Maya came in, looking worried. “Luna, I found something you need to see,” she says. “Remember Marcus Park? He tried releasing proprietary yeast information in 2039. Heineken buried him. He lost everything. His daughter dropped out of college. His wife left him. He’s working at a gas station now.” Luna spent the night researching what happened to Park. She found that almost everyone who challenged corporate IP ended up on the losing side of the law. It was not pretty. In the morning, Abuela Rosa finds her crying in her room. “Mija, what’s wrong?” she asks. “Oh, Abuela,” Luna says between sobs. “What am I doing? What if I’m wrong? What if I destroy our family? What if this ruins Mom and Dad? What if I’m just being selfish?” “That’s the fear talking.” Her grandmother reassured her. “Fear is wisdom warning you to be careful. But fear can also be a cage.” That evening at the Counter Culture Labs, Luna assembled a small group of advisors. She needed their guidance. She had the completed genetic sequences for Heineken A-yeast and Budweiser’s master strain on her laptop, ready for release. But is this the time and place to release them to the world? Dr. Marcus Webb, a bioinformatics researcher in his forties and Luna’s mentor, examined her sequencing data. “This is solid work, Luna. Your jury-rigged equipment is crude. The results are accurate. You’ve fully mapped both strains.” “The question isn’t whether I can do it,” Luna said. “It’s whether I should let the world know I did it.” On screen, Cory Doctorow, the author and digital rights activist, leaned forward. “Let’s be clear about what you’re proposing. You’d be releasing genetic information that corporations have protected as trade secrets for over a century. They’ll argue you stole their intellectual property. You’ll face lawsuits, possibly criminal charges.” “Is it their property?” Luna challenged. “These are naturally occurring organisms. They didn’t create that yeast. Evolution did. They just happened to be there when it appeared. That does not make it theirs any more than finding a wildflower means they own the species. Can you really own something that existed before you found it?” Doctorow, the Electronic Frontier Foundation representative spoke up. “There’s legal precedent both ways. Diamond v. Chakrabarty established that genetically modified organisms can be patented. But naturally occurring genetic sequences? That’s murky. The companies will argue that their decades of cultivation and protection created protectable trade secrets.” “Trade secrets require keeping information secret,” Luna argued. “They throw this yeast away constantly. If they’re not protecting it, how can they claim trade secret status?” Dr. Webb cautioned, “Luna, even if you’re legally in the right—which is debatable—you’re seventeen years old. You’ll be fighting multinational corporations with unlimited legal resources. They’ll bury you in litigation for years.” “That’s where we come in,” Doctorow said. “The EFF can provide legal defense. Creative Commons can help structure the license. You need to understand: this will consume your life. College, career plans, normal teenage experiences—all on hold while you fight this battle.” Luna was quiet for a moment, then pulled up a photo on her laptop: her grandmother Rosa, teaching her to ferment at age seven. “My abuela says fermentation is about sharing and passing living cultures between generations. Corporations have turned it into intellectual property to be protected and controlled. If I can break that control—even a little—isn’t that worth fighting for?” Maya spoke up from the back. “Luna, I love you, but you’re being naive. They won’t just sue you. They’ll make an example of you. Your face on every news channel, portrayed as a thief, a criminal. Our family harassed. Your future destroyed. For what? So people can brew beer with the same yeast as Heineken?” “Not just beer,” Luna responded passionately. “This is about whether living organisms can be owned. Whether genetic information—the code of life itself—can be locked behind intellectual property law. Yes, it starts with beer yeast. But what about beneficial bacteria? Life-saving microorganisms? Medicine-producing fungi? Where does it end?” Dr. Webb nodded slowly. “She’s right. This is bigger than beer. As biotech advances, genetic control becomes power over life itself. Do we want corporations owning that?” Doctorow sighed. “If you do this, Luna, do it right. Release everything simultaneously—BitTorrent, WikiLeaks, Creative Commons servers, distributed networks worldwide. Make it impossible to contain. Include complete cultivation protocols so anyone can reproduce your results. Make the data so damn widely available that suppressing it becomes futile.” “And write a manifesto,” he added. “Explain why you’re doing this. Frame the issue. Make it about principles, not piracy.” Luna nodded, fingers already typing. “When should I release?” “Pick a date with symbolic meaning,” Dr. Webb suggested. “Make it an event, not just a data dump.” Luna smiled. “December 15. The Bill of Rights Day. Appropriate for declaring biological rights, don’t you think?” Maya groaned. “You’re really doing this, aren’t you?” “Yes. I’m really doing this.” The Creative Commons Liberation On Tuesday, December 15, 2043—a date now celebrated as “Open Flavor Day”—Luna released the genetic sequences on multiple open-source networks. Her manifesto, titled Your Grandmother’s Yeast Is Your Birthright, argued that microbial genetics belonged to humanity’s shared heritage rather than corporate shareholders. It stated: Commercial companies have protected yeast strains for over a century. They’ve used intellectual property law to control flavor itself. But genetic information isn’t like a recipe or a formula—it’s biological code that evolved over millions of years before humans ever cultivated it. These strains are protected as trade secrets—the bacteria don’t belong to anyone. They existed before Heineken, before Budweiser, before trademark law. The companies just happened to isolate and cultivate them. Her data packages included DNA sequences and complete protocols for cultivating, modifying, and improving the strains. Luna’s releases came with user-friendly software that allowed amateur brewers to simulate genetic modifications before attempting them in real fermentations. Within 24 hours, over ten thousand people worldwide downloaded the files. The Creative Commons community erupted in celebration. Cory Doctorow’s blog post, The Teenager Who Stole Christmas (From Corporate Beer), went viral within hours. The Electronic Frontier Foundation immediately offered Luna legal protection, while the Free Software Foundation created the “Luna Defense Fund” to support her anticipated legal battles. The Legal Assault Heineken’s response was swift. The company filed emergency injunctions in 12 countries simultaneously, seeking to prevent the distribution of its “stolen intellectual property.” Their legal team, led by former U.S. Attorney General William Barr III, demanded Luna’s immediate arrest for “economic terrorism” and “theft of trade secrets valued at over $50 billion.” Anheuser-Busch’s reaction was even more extreme. CEO Marcel Telles IV appeared on CNBC, calling Luna “a bioterrorist who threatens the foundation of American capitalism.” The company hired private investigators to surveil Luna’s family and offered a $10 million reward for information leading to her prosecution. Their legal filing compared Luna’s actions to “stealing the formula for Coca-Cola and publishing it in the New York Times.” In Heineken’s Amsterdam headquarters, executives convened an emergency meeting. “Who is Luna Reyes?” the CEO demanded. The legal counsel pulled up information. “She’s a seventeen-year-old high school student in Oakland, California. No criminal record. Volunteers at a maker space. Has been posting about fermentation on various forums for years.” “A child released our proprietary yeast strain to the world, and we didn’t know she was even working on this?” The CEO’s face reddened. “How do we contain it?” “We can’t. It’s distributed across thousands of servers in dozens of countries with different IP laws. We can sue Reyes, but the information is out there permanently.” An executive interjected, “What about the other breweries? Will they join our lawsuit?” “Some are considering it. Others…” The counsel paused. “Others are quietly downloading the sequences themselves. They see an opportunity to break our market dominance.” “She obtained samples from our waste disposal,” another executive explained. “Technically legal under the garbage doctrine. The sequencing itself isn’t illegal. The release under Creative Commons…” “Is theft!” the CEO shouted. “File emergency injunctions. Twelve countries. Get her arrested for economic terrorism.” Similar scenes played out at Anheuser-Busch headquarters in St. Louis. CEO Telles addressed his team: “This is bioterrorism. She’s destroyed intellectual property worth billions. I want her prosecuted to the fullest extent of the law. Hire private investigators. Find everything about her and her family. Make her life hell!” By noon, both companies had filed lawsuits. By evening, Fox News was running stories about the “teenage bioterrorist” who “stole American corporate secrets.” Back in Oakland, Luna’s phone rang constantly. Her parents discovered what she’d done. Her mother cried. Her father was furious and terrified. Friends called with either congratulations or warnings. She was convinced that private investigators were photographing their house. Maya suspected she was followed to work. On Wednesday morning, Dr. Webb calls: “Luna, they’re offering me $2 million to testify against you. They’re going after everyone in your network.” Luna has a sickening feeling that she’s put everyone at risk. By Thursday, she is considering taking it all back somehow, sending an apology to the corporations, anything to protect her family. Luna turned off her phone and sat with her grandmother. “It’s started,” Luna said quietly. “Sí, mija. You’ve declared war. Now we see if you can survive it.” Maya burst in, laptop in hand. “Luna, you need to see this. The downloads aren’t slowing—they’re accelerating. Every time Heineken or Budweiser shuts down a website, ten mirror sites appear. People are treating this like a digital freedom fight. You’ve become a symbol.” Luna pulled up her own screen. The #FreeLuna hashtag was trending. Crowdfunding campaigns for her legal defense had raised $400,000 in twelve hours. Academic institutions were publicly endorsing her release, calling it “essential scientific information.” “They’re trying to destroy you,” Maya said, “but they’re making you famous instead.” Rosa handed Luna a fresh kombucha. “This is what happens when you fight for what’s right, mija. Sometimes the world surprises you by supporting you.” Luna’s Fame The corporations’ attempts to suppress Luna’s releases had the opposite effect. Every cease-and-desist letter generated thousands of new downloads. The genetic data became impossible to contain once the academic community embraced Luna’s work. Dr. Jennifer Doudna, the legendary Crispr pioneer now in her eighties, publicly endorsed Luna’s releases in a Science magazine editorial: Ms. Reyes has liberated essential scientific information that corporations held hostage for commercial gain. Genetic sequences from naturally occurring organisms should not be locked behind intellectual property law. They belong to humanity’s knowledge commons. While corporations claim Luna stole trade secrets, I argue she freed biological knowledge that was never theirs to own. There are no trade secrets in biology—only knowledge temporarily hidden from the commons. This is civil disobedience of the highest order—breaking unjust laws to advance human freedom. Ms. Reyes didn’t steal; she liberated. MIT’s biology department invited Luna to lecture, while Harvard offered her a full scholarship despite her lack of a high school diploma. The legal battles consumed corporate resources while generating negative publicity. Heineken’s stock price dropped 34% as consumers organized boycotts in support of Luna’s “yeast liberation.” Beer sales plummeted as customers waited for home-brewed alternatives using Luna’s open-source genetics. The Flavor Renaissance Luna’s releases triggered an explosion of creativity that corporate R&D departments had never imagined. Within six months, amateur brewers worldwide were producing thousands of flavor variations impossible under corporate constraints. The open-source model enabled rapid iteration and global collaboration, rendering traditional brewing companies obsolete. The world was engaged. In some of the most unlikely places. In Evanston, Illinois, a group of former seminary students who discovered fermentation during a silent retreat, transformed Gregorian chants into microbial devotionals. Tenor Marcus Webb (Dr. Webb’s nephew) realized symbiosis mirrored vocal harmony—multiple voices creating something greater than their parts. “In honoring the mystery of fermentation we express our love of the Creator,” he said. Here's ‘Consortium Vocalis' honoring the mother SCOBY. [Chorus]Our SCOBYIs pureOur SCOBYIs strongOur SCOBYKnows no boundariesOur SCOBYStrengthens as it fermentsOur SCOBYIs bacteria and yeast Our SCOBYTurns sucrose into glucose and fructoseIt ferments these simple sugars into ethanol and carbon dioxide,Acetic acid bacteria oxidize much of that ethanol into organic acidsSuch as acetic, gluconic, and other acids.This steadily lowers the pHMaking the tea taste sour-tangy instead of purely sweet. [Chorus] Our SCOBYThen helps microbes produce acids, enzymes, and small amounts of B‑vitaminsWhile probiotics grow in the liquid.The pH falls to help inhibit unwanted microbesOur SCOBY creates a self-preserving, acidic environment in the tea [Chorus] In Kingston, Jamaica, Rastafarian’s combined an award-winning kombucha sequenced in Humboldt County, California, with locally grown ganja into a sacramental beverage to help open their mind to reasoning and focus on Jah. Once fermented, it was consumed over the course of a three-day Nyabinghi ceremony. “Luna Reyes is truly blessed. She strengthened our unity as a people, and our Rastafari’ booch help us chant down Babylon,” a Rasta man smiled, blowing smoke from a spliff the size of his arm. The Groundation Collective’s reggae anthem ‘Oh Luna’ joyfully celebrated Luna Reyes’ pioneering discovery. Oh Luna, Oh Luna, Oh Luna ReyesI love the sound of your nameYou so deserve your fame Luna, Luna, Oh Luna ReyesShining brightYou warm my heart Luna, Luna, Oh Luna ReyesYou cracked the codeTeenage prophet, fermentation queenSymbiosis roadA genius at seventeen Oh Luna, Luna, Luna ReyesBeautiful moonMakes me swoon Oh Luna, Luna, Luna ReyesFreedom to fermentYou are heaven sentTo save us Luna, Luna, Oh Luna ReyesYou opened the doorTo so much moreKombucha tastes so goodLike it should Oh Luna, Oh Luna, Oh LunaI love you, love you, love youOh Luna, Luna, LunaLove you, love you,Love Luna, Luna love. In São Paulo, Brazil, MAPA-certified Brazilian kombucha brands combined Heineken and cacao-fermenting yeasts with cupuaçu from indigenous Amazonian peoples, to create the chocolate-flavored ‘booch that won Gold at the 20th World Kombucha Awards. A cervejeiro explained to reporters: “Luna Reyes gave us the foundation. We added local innovation. This is what happens when you democratize biology.” The Brazilian singer Dandara Sereia covered ‘Our Fermented Future’—The Hollow Pines tune destined to become a hit at the 2053 Washington DC Fermentation Festival. Baby sit a little closer, sip some ‘booch with meI brewed this batch with the SCOBY my grandma gave to me.On the back porch swing at twilight, watching fireflies danceYour hand in mine, kombucha fine, the sweetest sweet romance. They say that wine and roses are the way to win the heartBut your kombucha warmed me right up from the start.Fermentation makes the heart grow fonder, truer words they ain’t been saidYour SCOBY’s got a place forever — in my heart, and in my bed. Let’s share our SCOBYs, baby, merge our ferments into oneLike cultures in a crock jar dancing, underneath the sun.The tang of your Lactobacillus is exactly what I’m missingYour Brettanomyces bacteria got this country girl reminiscing. Oh yeah, let’s share those SCOBYs, baby, merge our ferments into oneYour yeasts and my bacteria working till the magic’s doneYou’ve got the acetic acid honey, I’ve got the patience and the timeLet’s bubble up together, let our cultures intertwine. I’ve got that symbiotic feeling, something wild and something trueYour SCOBY’s in my heart, right there next to youThe way your Acetobacter turns sugar into goldIs how you turned my lonely life into a hand to hold. We’ve got the acetic acid and the glucuronic tooWe’ve got that symbiotic feeling, so righteous and so trueOne sip of your sweet ‘booch, Lord, and you had me from the start,It’s our fermented future, that no-one can tear apart. It’s our fermented future…It’s our fermented future…It’s our fermented future… “Luna Variants”—strains derived from her releases—began winning international brewing competitions, embarrassing corporate entries with their complexity and innovation. Traditional beer flavors seemed flat and artificial compared to the genetic symphonies created by collaborative open-source development. Despite the outpouring of positive vibes, the corporations spared no expense to hold Luna to account in the courts. The Preliminary Hearing A preliminary hearing was held in the United States District Court for the Northern District of California on June 14, 2044. Luna sat at the defendant’s table, her hands folded so tightly her knuckles had gone white. She wore a borrowed blazer—too big in the shoulders—over a white button-down shirt Maya had ironed that morning. At seventeen, she looked even younger under the courtroom’s fluorescent lights. Across the aisle, Heineken’s legal team occupied three tables. Fifteen attorneys in matching navy suits shuffled documents and whispered into phones. Their lead counsel, William Barr III, wore gold cufflinks that caught the light when he gestured. Luna recognized him from the news—the former Attorney General, now commanding $2,000 an hour to destroy people like her. Her own legal representation consisted of two people: Rose Kennerson from the Electronic Frontier Foundation, a public interest lawyer who’d flown in from DC on a red-eye, and Dr. Marcus Webb, technically a witness but sitting beside Luna because she’d asked him to. Behind them, the gallery was packed. Luna’s parents sat in the second row, her father’s face gray, her mother clutching a rosary. Maya had taken the day off work. Abuela Rosa sat in the front row directly behind Luna, her ancient SCOBY wrapped in silk in her lap, as if its presence might protect her granddaughter. Judge Catherine Ironwood entered—sixty-ish, steel-gray hair pulled back severely, known for pro-corporate rulings. She’d been a pharmaceutical industry lawyer for twenty years before her appointment. “All rise,” the bailiff called. Judge Ironwood settled into her chair and surveyed the courtroom with the expression of someone who’d already decided the outcome and resented having to perform the formalities. “We’re here for a preliminary injunction hearing in Heineken International B.V. versus Luna Marie Reyes.” She looked directly at Luna. “Ms. Reyes, you’re seventeen years old?” Luna stood, hesitant. “Yes, your honor.” “Where are your parents?” “Here, your honor.” Luna’s mother half-rose, then sat back down. “Ms. Kennerson, your client is a minor. Are the parents aware they could be held liable for damages?” Rose Kennerson stood smoothly. “Yes, your honor. The Reyes family has been fully advised of the legal implications.” Luna glanced back. Her father’s jaw was clenched so tight she could see the muscles working. He wouldn’t meet her eyes. “Very well. Mr. Barr, you may proceed.” Barr rose like a battleship emerging from fog—massive, expensive, inevitable. He buttoned his suit jacket and approached the bench without notes. “Your honor, this is the simplest case I’ve argued in thirty years. The defendant admits to obtaining my client’s proprietary biological materials. She admits to sequencing their genetic information. She admits to distributing that information globally, in deliberate violation of trade secret protections that have existed for over 150 years. She did this knowingly, systematically, and with the explicit intent to destroy my client’s competitive advantage.” Luna felt Sarah’s hand on her arm—stay calm. Barr continued. “Heineken International has invested over $200 million in the development, cultivation, and protection of the A-yeast strain. Then this teenager”—he pointed at Luna—”obtained samples from our waste disposal systems, reverse-engineered our genetic sequences, and released them to the world via BitTorrent, deliberately placing them beyond retrieval.” He paced now, warming to his theme. “The damage is incalculable. We estimate lost market value at $50 billion. But it’s not just about money. The defendant has destroyed the possibility of competition in the brewing industry. When everyone has access to the same genetic materials, there’s no innovation, no differentiation, no reason for consumers to choose one product over another. She has, in effect, communized an entire industry.” Luna couldn’t help herself. “That’s not—” Sarah grabbed her wrist. “Don’t.” Judge Ironwood’s eyes narrowed. “Ms. Reyes, you will have your opportunity to speak. Until then, you will remain silent, or I will have you removed from this courtroom. Do you understand?” “Yes, your honor.” Luna’s voice came out smaller than she intended. Barr smiled slightly. “Your honor, the relief we seek is straightforward. We ask this court to order the defendant to provide us with a complete list of all servers, websites, and distribution networks where the stolen genetic data currently resides. We ask that she be ordered to cooperate fully in suppressing the data. We ask that she be enjoined from any further distribution. And we ask that she be ordered to pay compensatory damages of $5 billion, plus punitive damages to be determined at trial.” He returned to his seat. One of his associate attorneys handed him a bottle of Pellegrino. He took a sip and waited. Judge Ironwood looked at Sarah. “Ms. Kennerson?” Sarah stood. She looked tiny compared to Barr—five-foot-three, maybe 110 pounds, wearing a suit from Target. But when she spoke, her voice filled the courtroom. “Your honor, Mr. Barr has given you a compelling story about a corporation that’s been wronged. But it’s not the right story. The right story is about whether naturally occurring organisms—creatures that evolved over millions of years, long before humans ever existed—can be owned by a corporation simply because that corporation happened to isolate them.” She walked toward the bench. “Let’s be clear about what the A-yeast strain is. It’s not a genetically modified organism. It’s not a patented invention. It’s a naturally occurring yeast. Heineken didn’t create it. Evolution created it. Heineken merely found it. And for 158 years, they’ve claimed that finding something gives them the right to prevent anyone else from studying it, understanding it, or using it.” Barr was on his feet. “Objection, your honor. This is a preliminary hearing about injunctive relief, not a philosophical debate about intellectual property theory.” “Sustained. Ms. Kennerson, please focus on the specific legal issues before this court.” “Your honor, the specific legal issue is whether naturally occurring genetic sequences constitute protectable trade secrets. My client contends they do not. She obtained the yeast samples from Heineken’s waste disposal—materials they had discarded. Under the garbage doctrine, she had every right to analyze those materials. The genetic sequences she discovered are factual information about naturally occurring organisms. You cannot trade-secret facts about nature.” Luna watched Judge Ironwood’s face. Nothing. No reaction. Sarah pressed on. “Mr. Barr claims my client ‘stole’ genetic information worth $5 billion. But information cannot be stolen—it can only be shared. When I tell you a fact, I don’t lose possession of that fact. We both have it. That’s how knowledge works. Heineken hasn’t lost their yeast. They still have it. They can still brew with it. What they’ve lost is their monopoly on that knowledge. And monopolies on facts about nature should never have existed in the first place.” “Your honor—” Barr tried to interrupt. Judge Ironwood waved him down. “Continue, Ms. Kennerson.” “Your honor, Heineken wants this court to order a seventeen-year-old girl to somehow suppress information that has already been distributed to over 100,000 people in 147 countries. That’s impossible. You can’t unring a bell. You can’t put knowledge back in a bottle. Even if this court ordered my client to provide a list of servers—which she shouldn’t have to do—that list would be incomplete within hours as new mirror sites appeared. The information is out. The only question is whether we punish my client for sharing factual information about naturally occurring organisms.” She turned to face Luna’s family. “Ms. Reyes taught herself bioinformatics from YouTube videos. She works at home with equipment she bought on eBay. She has no criminal record. She’s never been in trouble. She saw a question that interested her—why do commercial beers taste like they do?—and she pursued that question with the tools available to her. When she discovered the answer, she shared it with the world, under a Creative Commons license that specifically protects sharing for educational and scientific purposes. If that’s terrorism, your honor, then every scientist who’s ever published a research paper is a terrorist.” Sarah sat down. Luna wanted to hug her. Judge Ironwood leaned back. “Ms. Reyes, stand up.” Luna rose, her legs shaking. “Do you understand the seriousness of these proceedings?” “Yes, your honor.” “Do you understand that Heineken International is asking me to hold you in contempt of court if you refuse to help them suppress the information you released?” “Yes, your honor.” “Do you understand that contempt of court could result in your detention in a juvenile facility until you reach the age of eighteen, and potentially longer if the contempt continues?” Luna’s mother gasped audibly. Her father put his arm around her. “Yes, your honor,” Luna said, though her voice wavered. “Then let me ask you directly: If I order you to provide Heineken with a complete list of all locations where the genetic data you released currently resides, will you comply?” The courtroom went silent. Luna could hear her own heartbeat. Sarah started to stand—”Your honor, I advise my client not to answer—” “Sit down, Ms. Kennerson. I’m asking your client a direct question. She can choose to answer or not.” Judge Ironwood’s eyes never left Luna. “Well, Ms. Reyes? Will you comply with a court order to help Heineken suppress the information you released?” Luna looked at her parents. Her mother was crying silently. Her father’s face was stone. She looked at Abuela Rosa. Her grandmother nodded once—tell the truth. Luna looked back at the judge. “No, your honor.” Barr shot to his feet. “Your honor, the defendant has just admitted she intends to defy a court order—” “I heard her, Mr. Barr.” Judge Ironwood’s voice was ice. “Ms. Reyes, do you understand you’ve just told a federal judge you will refuse a direct order?” “Yes, your honor.” “And you’re still refusing?” “Yes, your honor.” “Why?” Sarah stood quickly. “Your honor, my client doesn’t have to explain—” “I want to hear it.” Judge Ironwood leaned forward. “Ms. Reyes, tell me why you would risk jail rather than help undo what you’ve done.” Luna took a breath. Her whole body was shaking, but her voice was steady. “Because it would be wrong, your honor.” “Wrong how?” “The genetic sequences I released evolved over millions of years. Heineken didn’t create that yeast. They isolated one strain and claimed ownership of it. The code of life belongs to everyone. That’s humanity’s heritage. Even if you send me to jail, I can’t help suppress the truth.” Judge Ironwood stared at her for a long moment. “That’s a very pretty speech, Ms. Reyes. But this court operates under the law, not your personal philosophy about what should or shouldn’t be owned. Trade secret law exists. Heineken’s rights exist. And you violated those rights.” Luna did not hesitate. “With respect, your honor, I don’t think those rights should exist.” Barr exploded. “Your honor, this is outrageous! The defendant is openly stating she believes she has the right to violate any law she disagrees with—” “That’s not what I said.” Luna’s fear was transforming into something else—something harder. “I’m saying that some laws are unjust. And when laws are unjust, civil disobedience becomes necessary. People broke unjust laws during the civil rights movement. People broke unjust laws when they helped slaves escape. The constitution says members of the military do not have to obey illegal orders, despite what those in power might claim. Sometimes the law is wrong. And when the law says corporations can own genetic information about naturally occurring organisms, the law is wrong.” Judge Ironwood’s face flushed. “Ms. Reyes, you are not Rosa Parks. This is not the civil rights movement. This is a case about intellectual property theft.” “It’s a case about whether life can be property, your honor.” “Enough.” Judge Ironwood slammed her gavel. “Ms. Kennerson, control your client.” Sarah pulled Luna back into her chair. “Luna, stop talking,” she hissed. Judge Ironwood shuffled papers, visibly trying to compose herself. “I’m taking a fifteen-minute recess to consider the injunction request. We’ll reconvene at 11:30. Ms. Reyes, I strongly suggest you use this time to reconsider your position.” The gavel fell again, and Judge Ironwood swept out. The hallway outside the courtroom erupted. Reporters swarmed. Luna’s father grabbed her arm and pulled her into a witness room. Her mother followed, still crying. Maya slipped in before Sarah closed the door. “What were you thinking?” Luna’s father’s voice shook. “You just told a federal judge you’ll defy her orders. They’re going to put you in jail, Luna. Do you understand that? Jail!” “Ricardo, please—” Her mother tried to calm him. “No, Elena. Our daughter just committed contempt of court in front of fifty witnesses. They’re going to take her from us.” He turned to Luna, his eyes wet. “Why? Why couldn’t you just apologize? Say you made a mistake? We could have ended this.” “Because I didn’t make a mistake, Papa.” “You destroyed their property!” “It wasn’t their property. It was never their property.” “The law says it was!” “Then the law is wrong!” Her father stepped back as if she’d slapped him. “Do you know what your mother and I have sacrificed to keep you out of trouble? Do you know how hard we’ve worked since we came to this country to give you opportunities we never had? And you throw it away for yeast. Not for justice. Not for people. For yeast.” Luna’s eyes filled with tears. “It’s not about yeast, Papa. It’s about whether corporations get to own life. If Heineken can own yeast, why not bacteria? Why not human genes? Where does it stop?” “It stops when my daughter goes to jail!” He was shouting now. “I don’t care about Heineken. I don’t care about yeast. I care about you. And you just told that judge you’ll defy her. She’s going to put you in jail, and there’s nothing I can do to stop it.” “Ricardo, por favor—” Elena put her hand on his arm. He shook it off. “No. She needs to hear this. Luna, if you go to jail, your life is over. No college will accept you. No company will hire you. You’ll have a criminal record. You’ll be marked forever. Is that what you want?” “I want to do what’s right.” “What’s right is protecting your family! What’s right is not destroying your future for a principle!” he said. Luna responded, “What’s right is not letting corporations own the code of life!”They stared at each other. Maya spoke up quietly from the corner. “Papa, she can’t back down now. The whole world is watching.” “Let the world watch someone else!” Ricardo turned on Maya. “You encourage this. You film her, you post her manifestos online, you help her become famous. You’re her sister. You’re supposed to protect her, not help her destroy herself.” “I am protecting her,” Maya said. “I’m protecting her from becoming someone who backs down when the world tells her she’s wrong, even though she knows she’s right.” Ricardo looked between his daughters. “Ambos están locos! You’re both insane.” Abuela Rosa opened the door and entered. She’d been listening from the hallway. “Ricardo, enough.” “Mama, stay out of this.” “No.” Rosa moved between Ricardo and Luna. “You’re afraid. I understand. But fear makes you cruel, mijo. Your daughter is brave. She’s doing something important. And you’re making her choose between you and what’s right. Don’t do that.” “She’s seventeen years old! She’s a child!” “She’s old enough to know right from wrong.” Rosa put her hand on Ricardo’s cheek. “When I was sixteen, I left Oaxaca with nothing but the clothes on my back and this SCOBY. Everyone said I was crazy. Your father said I would fail. But I knew I had to go, even if it cost me everything. Sometimes our children have to do things that terrify us. That’s how the world changes.” Ricardo pulled away. “If they put her in jail, will that change the world, Mama? When she’s sitting in a cell while Heineken continues doing whatever they want, will that have been worth it?” “Yes,” Luna said quietly. “Even if I go to jail, yes. Because thousands of people now have the genetic sequences, Heineken can’t put that back. They can punish me, but they can’t undo what I did. The information is free. It’s going to stay free. And if the price of that is me going to jail, then that’s the price.” Her father looked at her as if seeing her for the first time. “I don’t know who you are anymore.” “I’m still your daughter, Papa. I’m just also someone who won’t let corporations own life.” A knock on the door. Sarah poked her head in. “They’re reconvening. Luna, we need to go.” Back in the courtroom, the atmosphere had shifted. The gallery was more crowded—word had spread during the recess. Luna recognized several people from online forums. Some held signs reading “FREE LUNA” and “GENETICS BELONG TO EVERYONE.” Judge Ironwood entered and sat without ceremony. “I’ve reviewed the submissions and heard the arguments. This is my ruling.” Luna’s hand found Maya’s in the row behind her. Squeezed tight. “The question before this court is whether to grant Heineken International’s motion for a preliminary injunction requiring Ms. Reyes to assist in suppressing the genetic information she released. To grant such an injunction, Heineken must demonstrate four things: likelihood of success on the merits, likelihood of irreparable harm without the injunction, balance of equities in their favor, and that an injunction serves the public interest.” Barr was nodding. These were his arguments. “Having considered the evidence and the applicable law, I find that Heineken has demonstrated likelihood of success on the merits. Trade secret law clearly protects proprietary business information, and the A-yeast strain appears to meet the legal definition of a trade secret.” Luna’s stomach dropped. “However, I also find that Heineken has failed to demonstrate that a preliminary injunction would effectively prevent the irreparable harm they claim. Ms. Kennerson is correct that the genetic information has already been distributed to over 100,000 people worldwide. Ordering one teenager to provide a list of servers would be, in technical terms, pointless. New copies would appear faster than they could be suppressed.” Barr’s face tightened. “Furthermore, I find that the balance of equities does not favor Heineken. They ask this court to potentially incarcerate a seventeen-year-old girl for refusing to suppress information that is, by her account, factual data about naturally occurring organisms. The potential harm to Ms. Reyes—including detention, criminal record, and foreclosure of educational and career opportunities—substantially outweighs any additional harm Heineken might suffer from continued distribution of information that is already widely distributed.” Luna felt Maya’s grip tighten. Was this good? This sounded good. “Finally, and most importantly, I find that granting this injunction would not serve the public interest. The court takes judicial notice that this case has generated substantial public debate about the scope of intellectual property protection in biotechnology. The questions raised by Ms. Reyes—whether naturally occurring genetic sequences should be ownable, whether facts about nature can be trade secrets, whether knowledge can be property—are questions that deserve answers from a higher authority than this court. These are questions for appellate courts, perhaps ultimately for the Supreme Court. And they are questions best answered in the context of a full trial on the merits, not in an emergency injunction hearing.” Barr was on his feet. “Your honor—” “Sit down, Mr. Barr. I’m not finished.” He sat, his face purple. “Therefore, Heineken International’s motion for preliminary injunction is denied. Ms. Reyes will not be required to assist in suppressing the genetic information she released. However,”—Judge Ironwood looked directly at Luna—”this ruling should not be construed as approval of Ms. Reyes’ actions. Heineken’s claims for damages and other relief remain viable and will proceed to trial. Ms. Reyes, you may have won this battle, but this war is far from over. Anything you want to say?” Luna stood slowly. “Your honor, I just want to say… thank you. For letting this go to trial. For letting these questions be answered properly. That’s all I ever wanted—for someone to seriously consider whether corporations should be allowed to own genetic information about naturally occurring organisms. So thank you.” Judge Ironwood’s expression softened slightly. “Ms. Reyes, I hope you’re prepared for what comes next. Heineken has unlimited resources. They will pursue this case for years if necessary. You’ll be in litigation until you’re twenty-five years old. Your entire young adulthood will be consumed by depositions, court appearances, and legal fees. Are you prepared for that?” “Yes, your honor.” “Why?” Luna glanced at her grandmother, who nodded. “Because some questions are worth answering, your honor. Even if it takes years. Even if it costs everything. The question of whether corporations can own life—that’s worth answering. And if I have to spend my twenties answering it, then that’s what I’ll do.” Judge Ironwood studied her for a long moment. “You remind me of someone I used to know. Someone who believed the law should serve justice, not just power.” She paused. “That person doesn’t exist anymore. The law ground her down. I hope it doesn’t do the same to you.” She raised her gavel. “This hearing is adjourned. The parties will be notified of the trial date once it’s scheduled. Ms. Reyes, good luck. I think you’re going to need it.” The gavel fell. Outside the courthouse, the scene was chaotic. News cameras surrounded Luna. Reporters shouted questions. But Luna barely heard them. She was looking at her father, who stood apart from the crowd, watching her. She walked over to him. “Papa, I’m sorry I yelled.” He didn’t speak for a moment. Then he pulled her into a hug so tight it hurt. “Don’t apologize for being brave,” he whispered into her hair. “I’m just afraid of losing you.” “You won’t lose me, Papa. I promise.” “You can’t promise that. Not anymore.” He pulled back, holding her shoulders. “But I’m proud of you. I’m terrified, but I’m proud.” Her mother joined them, tears streaming down her face. “No more court. Please, no more court.” “I can’t promise that either, Mama.” Elena touched Luna’s face. “Then promise me you’ll be careful. Promise me you’ll remember that you’re not just fighting for genetics. You’re fighting for your life.” Luna smiled. “I promise.” Abuela Rosa appeared, carrying her SCOBY. “Come, mija. We should go before the reporters follow us home.” As they pushed through the crowd toward Maya’s car, Luna's phone buzzed continuously. Text messages and emails pouring in. But what caught her attention was a text from Dr. Webb: You were right. I’m sorry I doubted. Check your email—Dr. Doudna wants to talk. Luna opened her email. The subject line made her stop walking: From: jennifer.doudna@berkeley.eduSubject: Civil Disobedience of the Highest Order She started to read: Dear Ms. Reyes, I watched your hearing this morning. What you did in that courtroom—refusing to back down even when threatened with jail—was one of the bravest things I’ve seen in forty years of science. You’re not just fighting for yeast genetics. You’re fighting for the principle that knowledge about nature belongs to humanity, not to corporations. I want to help… Luna looked up at her family—her father’s worried face, her mother’s tears, Maya’s proud smile, Abuela Rosa’s serene confidence. Behind them, the courthouse where she’d nearly been sent to jail. Around them, reporters and cameras and strangers who’d traveled across the country to support her. She thought about Judge Ironwood’s warning: This war is far from over. She thought about Barr’s face when the injunction was denied. She thought about the thousands who’d downloaded the genetic sequences and were, right now, brewing with genetics that had been locked away for 158 years. Worth it. All of it. Even the fear. Maya opened the car door. “Come on, little revolutionary. Let’s go home.” The Corporate Surrender By 2045, both Heineken and Anheuser-Busch quietly dropped their lawsuits against Luna. Their legal costs had exceeded $200 million while accomplishing nothing except generating bad publicity. More importantly, their “protected” strains had become worthless in a market flooded with superior alternatives. Heineken’s CEO attempted to salvage the company by embracing open-source brewing. His announcement that Heineken would “join the La Luna Revolution” was met with skepticism from the brewing community, which recalled the company’s aggressive legal tactics. The craft brewing community’s response was hostile. “They spent two years trying to destroy her,” a prominent brewmaster told The New Brewer Magazine. “Now they want credit for ’embracing’ the revolution she forced on them? Heineken didn’t join the Luna Revolution—they surrendered to it. There’s a difference.” The global brands never recovered their market share. Luna’s Transformation Luna’s success transformed her from a garage tinkerer into a global icon of the open knowledge movement. Her 2046 TED Talk, “Why Flavor Belongs to Everyone,” went viral. She argued that corporate control over living organisms represented “biological colonialism” that impoverished human culture by restricting natural diversity. Rather than commercializing her fame, Luna founded the Global Fermentation Commons, a nonprofit organization dedicated to preserving and sharing microbial genetics worldwide. Their laboratories operated as open-access research facilities where anyone could experiment with biological systems. The headquarters of the Global Fermentation Commons occupied a former Genentech facility donated by Dr. Webb. Six continents, forty researchers, one mission: preserve and share microbial genetics worldwide. Luna addressed a crowded auditorium at the organization’s third anniversary. “When I released Heineken and Budweiser’s yeast strains, some people called it theft. Others called it liberation. I called it returning biological knowledge to the commons, where it belongs. Three years later, so-called Luna Variants have created economic opportunities for thousands of small brewers, improved food security in developing regions, and demonstrated that genetic freedom drives innovation faster than corporate control.” She continued. “We’re not stopping with beer. The same principles apply to all fermentation: cheese cultures, yogurt bacteria, koji fungi, sourdough starters. Every traditionally fermented food relies on microorganisms that corporations increasingly claim to own. We’re systematically liberating them.” A World Health Organization representative raised a concern: “Ms. Reyes, while we support democratizing food fermentation, there are legitimate concerns about pharmaceutical applications. What prevents someone from using your open-source genetics to create dangerous organisms?” Luna nodded. “Fair question. First, the organisms we release are food-safe cultures with centuries of safe use. Second, dangerous genetic modifications require sophisticated laboratory equipment and expertise—far beyond what releasing genetic sequences enables. Third, determined bad actors already have access to dangerous biology, enabled by AI. We’re not creating new risks; we’re democratizing beneficial biology.” “Pharmaceutical companies argue you’re undermining their investments in beneficial organisms,” another representative pressed. “Pharmaceutical companies invest in modifying organisms,” Luna clarified. “Those modifications can be patented. What we oppose is claiming ownership over naturally occurring organisms or their baseline genetics. If you genetically engineer a bacterium to produce insulin, patent your engineering. Don’t claim ownership over the bacterial species itself.” A Monsanto representative stood. “Your organization recently cracked and released our proprietary seed genetics. That’s direct theft of our property.” Luna didn’t flinch. “Seeds that farmers cultivated for thousands of years before Monsanto existed? You didn’t invent corn, wheat, or soybeans. You modified them. Your modifications may be protectable; the baseline genetics are humanity’s heritage. We’re liberating what should never have been owned.” “The ‘Luna Legion’ has cost us hundreds of millions!” the representative protested. “Good,” Luna responded calmly. “You’ve cost farmers their sovereignty for decades. Consider it karma.” After the presentation, Dr. Doudna approached Luna privately. “You’ve accomplished something remarkable,” the elderly scientist said. “When I developed Crispr, I never imagined a teenager would use similar principles to challenge corporate biology. You’re forcing conversations about genetic ownership that we’ve avoided for decades.” “It needed forcing,” Luna replied. “Corporations were quietly owning life itself, one patent at a time. Someone had to say no.” “The pharmaceutical industry is terrified of you,” Doudna continued. “They see what happened to brewing and imagine the same for their carefully controlled bacterial strains. You’re going to face even more aggressive opposition.” “I know. Once people understand that biological knowledge can be liberated, they start questioning all biological ownership. We’re not stopping.” The New Economy of Taste Following Luna’s breakthrough, peer-to-peer flavor-sharing platforms emerged as the dominant force in food culture. The “FlavorChain” blockchain allowed brewers to track genetic lineages while ensuring proper attribution to original creators. SCOBY lineages were carefully sequenced, catalogued, and registered on global blockchain ledgers. Each award-winning kombucha strain carried a “genetic passport”—its microbial makeup, the unique balance of yeasts and bacteria that gave rise to particular mouthfeel, fizz, and flavor spectrum, was mapped, hashed, and permanently recorded. Brewers who created a new flavor could claim authorship, just as musicians once copyrighted songs. No matter how many times a SCOBY was divided, its fingerprint could be verified. Fermentation Guilds formed to share recipes through FlavorChain, enabling decentralized digital markets like SymbioTrdr, built on trust and transparency rather than speculation. They allowed people to interact and transact on a global, permissionless, self-executing platform. Within days, a SCOBY strain from the Himalayas could appear in a brew in Buenos Aires, its journey traced through open ledgers showing who tended, adapted, and shared it. Kombucha recipes were no longer jealously guarded secrets. They were open to anyone who wanted to brew. With a few clicks, a Guild member in Nairobi could download the blockchain-verified SCOBY genome that had won Gold at the Tokyo Fermentation Festival. Local biotech printers—as common in 2100 kitchens as microwave ovens had once been—could reconstitute the living culture cell by cell. Children began inheriting SCOBY lineages the way earlier generations inherited family names. Weddings combined SCOBY cultures as symbolic unions. (Let’s share our SCOBYs, baby, merge our ferments into one.) When someone died, their SCOBY was divided among friends and family—a continuation of essence through taste. Kombucha was no longer merely consumed; it was communed with. This transparency transformed kombucha from a minority regional curiosity into a universal language. A festival in Brazil might feature ten local interpretations of the same “Golden SCOBY” strain—one brewed with passionfruit, another with cupuaçu, a third with açaí berries. The core microbial signature remained intact, while the terroir of fruit and spice gave each version a unique accent. Brewers didn’t lose their craft—they gained a canvas. Award-winning SCOBYs were the foundations on which endless new flavor experiments flourished. Many people were now as prolific as William Esslinger, the founder of St Louis’s Confluence Kombucha, who was renowned for developing 800 flavors in the 2020s. Code of Symbiosis The Symbiosis Code, ratified at the first World Fermentation Gathering in Reykjavik (2063), bound Fermentation Guilds to three principles: Transparency — All microbial knowledge is to be shared freely. Reciprocity — No brew should be produced without acknowledging the source. Community — Every fermentation must nourish more than the brewer. This code replaced corporate law. It was enforced by reputation, not by governments. A Guild member who betrayed the code found their SCOBYs mysteriously refusing to thrive—a poetic justice the biologists never quite explained. Every Guild had elders—called Mothers of the Jar or Keepers of the Yeast. They carried living SCOBYs wrapped in silk pouches when traveling, exchanging fragments as blessings. These elders became moral anchors of the age, counselors and mediators trusted more than politicians. When disputes arose—over territory, resources, or ethics—brewers, not lawyers, met to share a round of Truth Brew, a ferment so balanced that it was said to reveal dishonesty through bitterness. The Fullness of Time The International Biotech Conference of 2052 invited Luna to give the closing keynote—a controversial decision that prompted several corporate sponsors to withdraw support. The auditorium was packed with supporters, critics, and the merely curious. “Nine years ago, I released genetic sequences for beer yeast strains protected as trade secrets. I was called a thief, a bioterrorist, worse. Today, I want to discuss what we’ve learned from those years of open-source biology.” She displayed a chart showing the explosion of brewing innovation since 2043. “In the traditional corporate model, a few companies control a few strains, producing a limited variety. With the open-source model, thousands of brewers using thousands of variants, producing infinite diversity. As Duff McDonald wrote “Anything that alive contains the universe, or infinite possibility. Kombucha is infinite possibility in a drink.” And the results speak for themselves—flavor innovation accelerated a thousand-fold when we removed corporate control.” A student activist approached the microphone. “Ms. Reyes, you’ve inspired movements to liberate seed genetics, soil bacteria, and traditional medicine cultures. The ‘Luna Legion’ is spreading globally. What’s your message to young people who want to continue this work?” Luna smiled. “First, understand the risks. I was sued by multinational corporations, received death threats, spent years fighting legal battles. This work has costs. Second, be strategic. Release information you’ve generated yourself through legal methods—no hacking, no theft. Third, build communities. I survived because people supported me—legally, financially, emotionally. You can’t fight corporations alone. Finally, remember why you’re doing it: to return biological knowledge to the commons where it belongs. That purpose will sustain you through the hard parts.” Teaching By twenty-eight, Luna was a MacArthur Fellow, teaching fermentation workshops in a converted Anheuser-Busch facility. As she watched her students—former corporate employees learning to think like ecosystems rather than factories—she reflected that her teenage hack had accomplished more than liberating yeast genetics. She had helped humanity remember that flavor, like knowledge, grows stronger when shared rather than hoarded. Luna’s garage had evolved into a sophisticated community biolab. The original jury-rigged equipment had been replaced with professional gear funded by her MacArthur Fellowship. Abuela Rosa still maintained her fermentation crocks in the corner—a reminder of where everything started. A group of five

This week, we look at new studies on early aspirin discontinuation after myocardial infarction, an antiviral pill for dengue prevention, and CRISPR-based gene editing for lipid disorders. We review bedside clinical teaching and present a complex case of seizures and visual disturbances. Perspectives explore antidepressant safety in pregnancy, restoring trust in public health, academic medical centers' venture investments, and a young physician's wrinkled white coat.

After our “AILIEN The Final Card” show, it became apparent that the push to grant mass “amnesty” to every person and agency involved in black budget programs was a dangerous narrative gaining more traction by the day, and now compounded by an executive order from the White House titled “Launching the Genesis Mission.” This program seeks to support, along with the AI regulation moratorium of the BBB, the narrative that “America is in a race for global technology dominance in the development of artificial intelligence (AI).” The first section states: “the challenges we face require a historic national effort, comparable in urgency and ambition to the Manhattan Project that was instrumental to our victory in World War II.” But what suddenly changed? Have other countries cracked the AI egg entirely or has, as the UFO community suggests, they reverse engineered alien tech fully? Even so, a dangerous nationwide Manhattan Project should be a secret, not a public initiative. One part of the EO says the goal is to develop "AI-enabled predictive models, simulation models, and design optimization tools,” things that have been sold to the public over and over again, from climate change to pandemic models, but which have all been wrong. But if AI says something is true based on a model, it must be correct. However, if AI is merely saying what is most likely based on current actions, like a tarot reading, then if all current policies are designed for war then isn't that what we will get? Isn't that what Alex Karp of Palantir said would happen? And isn't “Genesis” also “skynet”?For those left waiting for something “big” to happen it will be disappointing to learn that it already has. Engineered smart/micro-dust is currently turning the world into a giant sensor, while Sam Altman of the Stargate Project, OpenAI, and the Orb, is now funding CRISPR-based embryo gene editing as the alterer-of-man.And to keep us entertained during this slow-burn apocalyptic invasion, we have KION, an AI-created K-pop star who's clearly created with all he best black goo moments from Taylor Swift, Lady Gaga, Billie Eilish, and the like. It all makes sense if the gift of “UFO technology” may in fact be a series of blueprints to build the alien mind on earth; the name KION, from various languages, translates to ancient-foundation-leader-possessed. In other words, Lovecraft's Old Ones once more. But IT is being sold as a sexy black goo princess.  *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.WEBSITEFREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVE-X / TWITTERFACEBOOKINSTAGRAMYOUTUBERUMBLE - BUY ME A COFFEECashApp: $rdgable PAYPAL: rdgable1991@gmail.comRyan's Books: https://thesecretteachings.info-EMAIL: rdgable@yahoo.com / rdgable1991@gmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

A baffling decision by FDA to issue a complete response letter for a pediatric medicine the medical community stood behind is just the latest example raising concerns that the agency is shifting the regulatory goalposts amid a lack of transparency. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin explains how the absence of advisory committee meetings at FDA is in part to blame for a lack of consistency in decision-making and divergence from decisions taken by other global regulatory agencies. VP and Editor-in-Chief Simone Fishburn then discusses the takeaways from Franck Le Deu's guest commentary on how China's biotech ecosystem is evolving, and whether government support for the sector is helping or hindering its overall health. BioCentury's analysts also discuss whether conventional CRISPR therapies will ever be commercially successful, and what's next for NLRP3 inhibitors to treat obesity following the first set of Phase II data for the class.We'd also like to invite our listeners to participate in our important survey about their experiences interacting with FDA. To take the survey, please go to BioCentury's FDA Sentiment Survey. This episode of the BioCentury This Week podcast is brought to you by Voyager Therapeutics.View full story: https://www.biocentury.com/article/657698#FDARegulation #CRISPRTherapies #NLRP3Inhibitors #ChinaBiotech #DrugApproval00:01 - Sponsor Message: Voyager Therapeutics01:31 - FDA Sydnexis CRL07:36 - CDC Vaccine Claims09:55 - China's Innovation Arc16:49 - CRISPR Commercial Viability 26:39 - NLRP3 for ObesityTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Synopsis: This episode is proudly sponsored by Quartzy. Biotech is undergoing a scientific redesign, and Jason Kelly reveals to host Alok Tayi how automation, AI-ready datasets, and modular lab technologies are reshaping the future of R&D. Jason explains why legacy biopharma data—messy, inconsistent, and lacking metadata—cannot power modern machine learning, and why the industry must generate entirely new, massively standardized experimental datasets to unlock AI's true potential. He walks through Ginkgo's evolution from platform partnerships to a next-generation CRO built for AI-driven discovery, offering industrialized functional genomics, mammalian engineering, CRISPR libraries, and high-throughput developability assays at unprecedented scale. Jason also describes how Ginkgo's reconfigurable automation systems—robotic building blocks that replace 18-month custom builds—are democratizing high-throughput experimentation and making advanced lab infrastructure as flexible as cloud computing. Together, Jason and Alok explore how the fusion of automation and AI can collapse R&D timelines, rewrite cost structures, and enable thousands of new biotech companies to test ideas faster than ever before. For scientists, engineers, and AI practitioners, this episode offers a compelling look at the new scientific architecture emerging at the intersection of robotics, data, and programmable biology. Biography: Dr. Jason Kelly is the co-founder and CEO of Ginkgo Bioworks. He took the company public and raised $1.6B in the largest US biotech public listing to date in 2021. Today the company is pioneering autonomous labs that accelerate bioengineering across biopharma, agriculture, and industrial biotech industries. Jason also previously served as the Chair of the US National Security Commission on Emerging Biotechnology which oversees how advancements in emerging biotechnology will shape current and future activities of the US Department of Defense. Prior to Ginkgo, Jason received B.S. degrees in Chemical Engineering and Biology and a PhD in Biological Engineering all from MIT.

How can you write science-based fiction without info-dumping your research? How can you use AI tools in a creative way, while still focusing on a human-first approach? Why is adapting to the fast pace of change so difficult and how can we make the most of this time? Jamie Metzl talks about Superconvergence and more. In the intro, How to avoid author scams [Written Word Media]; Spotify vs Audible audiobook strategy [The New Publishing Standard]; Thoughts on Author Nation and why constraints are important in your author life [Self-Publishing with ALLi]; Alchemical History And Beautiful Architecture: Prague with Lisa M Lilly on my Books and Travel Podcast. Today's show is sponsored by Draft2Digital, self-publishing with support, where you can get free formatting, free distribution to multiple stores, and a host of other benefits. Just go to www.draft2digital.com to get started. This show is also supported by my Patrons. Join my Community at Patreon.com/thecreativepenn Jamie Metzl is a technology futurist, professional speaker, entrepreneur, and the author of sci-fi thrillers and futurist nonfiction books, including the revised and updated edition of Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World. You can listen above or on your favorite podcast app or read the notes and links below. Here are the highlights and the full transcript is below. Show Notes How personal history shaped Jamie's fiction writing Writing science-based fiction without info-dumping The super convergence of three revolutions (genetics, biotech, AI) and why we need to understand them holistically Using fiction to explore the human side of genetic engineering, life extension, and robotics Collaborating with GPT-5 as a named co-author How to be a first-rate human rather than a second-rate machine You can find Jamie at JamieMetzl.com. Transcript of interview with Jamie Metzl Jo: Jamie Metzl is a technology futurist, professional speaker, entrepreneur, and the author of sci-fi thrillers and futurist nonfiction books, including the revised and updated edition of Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World. So welcome, Jamie. Jamie: Thank you so much, Jo. Very happy to be here with you. Jo: There is so much we could talk about, but let's start with you telling us a bit more about you and how you got into writing. From History PhD to First Novel Jamie: Well, I think like a lot of writers, I didn't know I was a writer. I was just a kid who loved writing. Actually, just last week I was going through a bunch of boxes from my parents' house and I found my autobiography, which I wrote when I was nine years old. So I've been writing my whole life and loving it. It was always something that was very important to me. When I finished my DPhil, my PhD at Oxford, and my dissertation came out, it just got scooped up by Macmillan in like two minutes. And I thought, “God, that was easy.” That got me started thinking about writing books. I wanted to write a novel based on the same historical period – my PhD was in Southeast Asian history – and I wanted to write a historical novel set in the same period as my dissertation, because I felt like the dissertation had missed the human element of the story I was telling, which was related to the Cambodian genocide and its aftermath. So I wrote what became my first novel, and I thought, “Wow, now I'm a writer.” I thought, “All right, I've already published one book. I'm gonna get this other book out into the world.” And then I ran into the brick wall of: it's really hard to be a writer. It's almost easier to write something than to get it published. I had to learn a ton, and it took nine years from when I started writing that first novel, The Depths of the Sea, to when it finally came out. But it was such a positive experience, especially to have something so personal to me as that story. I'd lived in Cambodia for two years, I'd worked on the Thai-Cambodian border, and I'm the child of a Holocaust survivor. So there was a whole lot that was very emotional for me. That set a pattern for the rest of my life as a writer, at least where, in my nonfiction books, I'm thinking about whatever the issues are that are most important to me. Whether it was that historical book, which was my first book, or Hacking Darwin on the future of human genetic engineering, which was my last book, or Superconvergence, which, as you mentioned in the intro, is my current book. But in every one of those stories, the human element is so deep and so profound. You can get at some of that in nonfiction, but I've also loved exploring those issues in deeper ways in my fiction. So in my more recent novels, Genesis Code and Eternal Sonata, I've looked at the human side of the story of genetic engineering and human life extension. And now my agent has just submitted my new novel, Virtuoso, about the intersection of AI, robotics, and classical music. With all of this, who knows what's the real difference between fiction and nonfiction? We're all humans trying to figure things out on many different levels. Shifting from History to Future Tech Jo: I knew that you were a polymath, someone who's interested in so many things, but the music angle with robotics and AI is fascinating. I do just want to ask you, because I was also at Oxford – what college were you at? Jamie: I was in St. Antony's. Jo: I was at Mansfield, so we were in that slightly smaller, less famous college group, if people don't know. Jamie: You know, but we're small but proud. Jo: Exactly. That's fantastic. You mentioned that you were on the historical side of things at the beginning and now you've moved into technology and also science, because this book Superconvergence has a lot of science. So how did you go from history and the past into science and the future? Biology and Seeing the Future Coming Jamie: It's a great question. I'll start at the end and then back up. A few years ago I was speaking at Lawrence Livermore National Laboratory, which is one of the big scientific labs here in the United States. I was a guest of the director and I was speaking to their 300 top scientists. I said to them, “I'm here to speak with you about the future of biology at the invitation of your director, and I'm really excited. But if you hear something wrong, please raise your hand and let me know, because I'm entirely self-taught. The last biology course I took was in 11th grade of high school in Kansas City.” Of course I wouldn't say that if I didn't have a lot of confidence in my process. But in many ways I'm self-taught in the sciences. As you know, Jo, and as all of your listeners know, the foundation of everything is curiosity and then a disciplined process for learning. Even our greatest super-specialists in the world now – whatever their background – the world is changing so fast that if anyone says, “Oh, I have a PhD in physics/chemistry/biology from 30 years ago,” the exact topic they learned 30 years ago is less significant than their process for continuous learning. More specifically, in the 1990s I was working on the National Security Council for President Clinton, which is the president's foreign policy staff. My then boss and now close friend, Richard Clarke – who became famous as the guy who had tragically predicted 9/11 – used to say that the key to efficacy in Washington and in life is to try to solve problems that other people can't see. For me, almost 30 years ago, I felt to my bones that this intersection of what we now call AI and the nascent genetics revolution and the nascent biotechnology revolution was going to have profound implications for humanity. So I just started obsessively educating myself. When I was ready, I started writing obscure national security articles. Those got a decent amount of attention, so I was invited to testify before the United States Congress. I was speaking out a lot, saying, “Hey, this is a really important story. A lot of people are missing it. Here are the things we should be thinking about for the future.” I wasn't getting the kind of traction that I wanted. I mentioned before that my first book had been this dry Oxford PhD dissertation, and that had led to my first novel. So I thought, why don't I try the same approach again – writing novels to tell this story about the genetics, biotech, and what later became known popularly as the AI revolution? That led to my two near-term sci-fi novels, Genesis Code and Eternal Sonata. On my book tours for those novels, when I explained the underlying science to people in my way, as someone who taught myself, I could see in their eyes that they were recognizing not just that something big was happening, but that they could understand it and feel like they were part of that story. That's what led me to write Hacking Darwin, as I mentioned. That book really unlocked a lot of things. I had essentially predicted the CRISPR babies that were born in China before it happened – down to the specific gene I thought would be targeted, which in fact was the case. After that book was published, Dr. Tedros, the Director-General of the World Health Organization, invited me to join the WHO Expert Advisory Committee on Human Genome Editing, which I did. It was a really great experience and got me thinking a lot about the upside of this revolution and the downside. The Birth of Superconvergence Jamie: I get a lot of wonderful invitations to speak, and I have two basic rules for speaking: Never use notes. Never ever. Never stand behind a podium. Never ever. Because of that, when I speak, my talks tend to migrate. I'd be speaking with people about the genetics revolution as it applied to humans, and I'd say, “Well, this is just a little piece of a much bigger story.” The bigger story is that after nearly four billion years of life on Earth, our one species has the increasing ability to engineer novel intelligence and re-engineer life. The big question for us, and frankly for the world, is whether we're going to be able to use that almost godlike superpower wisely. As that idea got bigger and bigger, it became this inevitable force. You write so many books, Jo, that I think it's second nature for you. Every time I finish a book, I think, “Wow, that was really hard. I'm never doing that again.” And then the books creep up on you. They call to you. At some point you say, “All right, now I'm going to do it.” So that was my current book, Superconvergence. Like everything, every journey you take a step, and that step inspires another step and another. That's why writing and living creatively is such a wonderfully exciting thing – there's always more to learn and always great opportunities to push ourselves in new ways. Balancing Deep Research with Good Storytelling Jo: Yeah, absolutely. I love that you've followed your curiosity and then done this disciplined process for learning. I completely understand that. But one of the big issues with people like us who love the research – and having read your Superconvergence, I know how deeply you go into this and how deeply you care that it's correct – is that with fiction, one of the big problems with too much research is the danger of brain-dumping. Readers go to fiction for escapism. They want the interesting side of it, but they want a story first. What are your tips for authors who might feel like, “Where's the line between putting in my research so that it's interesting for readers, but not going too far and turning it into a textbook?” How do you find that balance? Jamie: It's such a great question. I live in New York now, but I used to live in Washington when I was working for the U.S. government, and there were a number of people I served with who later wrote novels. Some of those novels felt like policy memos with a few sex scenes – and that's not what to do. To write something that's informed by science or really by anything, everything needs to be subservient to the story and the characters. The question is: what is the essential piece of information that can convey something that's both important to your story and your character development, and is also an accurate representation of the world as you want it to be? I certainly write novels that are set in the future – although some of them were a future that's now already happened because I wrote them a long time ago. You can make stuff up, but as an author you have to decide what your connection to existing science and existing technology and the existing world is going to be. I come at it from two angles. One: I read a huge number of scientific papers and think, “What does this mean for now, and if you extrapolate into the future, where might that go?” Two: I think about how to condense things. We've all read books where you're humming along because people read fiction for story and emotional connection, and then you hit a bit like: “I sat down in front of the president, and the president said, ‘Tell me what I need to know about the nuclear threat.'” And then it's like: insert memo. That's a deal-killer. It's like all things – how do you have a meaningful relationship with another person? It's not by just telling them your story. Even when you're telling them something about you, you need to be imagining yourself sitting in their shoes, hearing you. These are very different disciplines, fiction and nonfiction. But for the speculative nonfiction I write – “here's where things are now, and here's where the world is heading” – there's a lot of imagination that goes into that too. It feels in many ways like we're living in a sci-fi world because the rate of technological change has been accelerating continuously, certainly for the last 12,000 years since the dawn of agriculture. It's a balance. For me, I feel like I'm a better fiction writer because I write nonfiction, and I'm a better nonfiction writer because I write fiction. When I'm writing nonfiction, I don't want it to be boring either – I want people to feel like there's a story and characters and that they can feel themselves inside that story. Jo: Yeah, definitely. I think having some distance helps as well. If you're really deep into your topics, as you are, you have to leave that manuscript a little bit so you can go back with the eyes of the reader as opposed to your eyes as the expert. Then you can get their experience, which is great. Looking Beyond Author-Focused AI Fears Jo: I want to come to your technical knowledge, because AI is a big thing in the author and creative community, like everywhere else. One of the issues is that creators are focusing on just this tiny part of the impact of AI, and there's a much bigger picture. For example, in 2024, Demis Hassabis from Google DeepMind and his collaborative partner John Jumper won the Nobel Prize for Chemistry with AlphaFold. It feels to me like there's this massive world of what's happening with AI in health, climate, and other areas, and yet we are so focused on a lot of the negative stuff. Maybe you could give us a couple of things about what there is to be excited and optimistic about in terms of AI-powered science? Jamie: Sure. I'm so excited about all of the new opportunities that AI creates. But I also think there's a reason why evolution has preserved this very human feeling of anxiety: because there are real dangers. Anybody who's Pollyanna-ish and says, “Oh, the AI story is inevitably positive,” I'd be distrustful. And anyone who says, “We're absolutely doomed, this is the end of humanity,” I'd also be distrustful. So let me tell you the positives and the negatives, and maybe some thoughts about how we navigate toward the former and away from the latter. AI as the New Electricity Jamie: When people think of AI right now, they're thinking very narrowly about these AI tools and ChatGPT. But we don't think of electricity that way. Nobody says, “I know electricity – electricity is what happens at the power station.” We've internalised the idea that electricity is woven into not just our communication systems or our houses, but into our clothes, our glasses – it's woven into everything and has super-empowered almost everything in our modern lives. That's what AI is. In Superconvergence, the majority of the book is about positive opportunities: In healthcare, moving from generalised healthcare based on population averages to personalised or precision healthcare based on a molecular understanding of each person's individual biology. As we build these massive datasets like the UK Biobank, we can take a next jump toward predictive and preventive healthcare, where we're able to address health issues far earlier in the process, when interventions can be far more benign. I'm really excited about that, not to mention the incredible new kinds of treatments – gene therapies, or pharmaceuticals based on genetics and systems-biology analyses of patients. Then there's agriculture. Over the last hundred years, because of the technologies of the Green Revolution and synthetic fertilisers, we've had an incredible increase in agricultural productivity. That's what's allowed us to quadruple the global population. But if we just continue agriculture as it is, as we get towards ten billion wealthier, more empowered people wanting to eat like we eat, we're going to have to wipe out all the wild spaces on Earth to feed them. These technologies help provide different paths toward increasing agricultural productivity with fewer inputs of land, water, fertiliser, insecticides, and pesticides. That's really positive. I could go on and on about these positives – and I do – but there are very real negatives. I was a member of the WHO Expert Advisory Committee on Human Genome Editing after the first CRISPR babies were very unethically created in China. I'm extremely aware that these same capabilities have potentially incredible upsides and very real downsides. That's the same as every technology in the past, but this is happening so quickly that it's triggering a lot of anxieties. Governance, Responsibility, and Why Everyone Has a Role Jamie: The question now is: how do we optimise the benefits and minimise the harms? The short, unsexy word for that is governance. Governance is not just what governments do; it's what all of us do. That's why I try to write books, both fiction and nonfiction, to bring people into this story. If people “other” this story – if they say, “There's a technology revolution, it has nothing to do with me, I'm going to keep my head down” – I think that's dangerous. The way we're going to handle this as responsibly as possible is if everybody says, “I have some role. Maybe it's small, maybe it's big. The first step is I need to educate myself. Then I need to have conversations with people around me. I need to express my desires, wishes, and thoughts – with political leaders, organisations I'm part of, businesses.” That has to happen at every level. You're in the UK – you know the anti-slavery movement started with a handful of people in Cambridge and grew into a global movement. I really believe in the power of ideas, but ideas don't spread on their own. These are very human networks, and that's why writing, speaking, communicating – probably for every single person listening to this podcast – is so important. Jo: Mm, yeah. Fiction Like AI 2041 and Thinking Through the Issues Jo: Have you read AI 2041 by Kai-Fu Lee and Chen Qiufan? Jamie: No. I heard a bunch of their interviews when the book came out, but I haven't read it. Jo: I think that's another good one because it's fiction – a whole load of short stories. It came out a few years ago now, but the issues they cover in the stories, about different people in different countries – I remember one about deepfakes – make you think more about the topics and help you figure out where you stand. I think that's the issue right now: it's so complex, there are so many things. I'm generally positive about AI, but of course I don't want autonomous drone weapons, you know? The Messy Reality of “Bad” Technologies Jamie: Can I ask you about that? Because this is why it's so complicated. Like you, I think nobody wants autonomous killer drones anywhere in the world. But if you right now were the defence minister of Ukraine, and your children are being kidnapped, your country is being destroyed, you're fighting for your survival, you're getting attacked every night – and you're getting attacked by the Russians, who are investing more and more in autonomous killer robots – you kind of have two choices. You can say, “I'm going to surrender,” or, “I'm going to use what technology I have available to defend myself, and hopefully fight to either victory or some kind of stand-off.” That's what our societies did with nuclear weapons. Maybe not every American recognises that Churchill gave Britain's nuclear secrets to America as a way of greasing the wheels of the Anglo-American alliance during the Second World War – but that was our programme: we couldn't afford to lose that war, and we couldn't afford to let the Nazis get nuclear weapons before we did. So there's the abstract feeling of, “I'm against all war in the abstract. I'm against autonomous killer robots in the abstract.” But if I were the defence minister of Ukraine, I would say, “What will it take for us to build the weapons we can use to defend ourselves?” That's why all this stuff gets so complicated. And frankly, it's why the relationship between fiction and nonfiction is so important. If every novel had a situation where every character said, “Oh, I know exactly the right answer,” and then they just did the right answer and it was obviously right, it wouldn't make for great fiction. We're dealing with really complex humans. We have conflicting impulses. We're not perfect. Maybe there are no perfect answers – but how do we strive toward better rather than worse? That's the question. Jo: Absolutely. I don't want to get too political on things. How AI Is Changing the Writing Life Jo: Let's come back to authors. In terms of the creative process, the writing process, the research process, and the business of being an author – what are some of the ways that you already use AI tools, and some of the ways, given your futurist brain, that you think things are going to change for us? Jamie: Great question. I'll start with a little middle piece. I found you, Jo, through GPT-5. I asked ChatGPT, “I'm coming out with this book and I want to connect with podcasters who are a little different from the ones I've done in the past. I've been a guest on Joe Rogan twice and some of the bigger podcasts. Make me a list of really interesting people I can have great conversations with.” That's how I found you. So this is one reward of that process. Let me say that in the last year I've worked on three books, and I'll explain how my relationship with AI has changed over those books. Cleaning Up Citations (and Getting Burned) Jamie: First is the highly revised paperback edition of Superconvergence. When the hardback came out, I had – I don't normally work with research assistants because I like to dig into everything myself – but the one thing I do use a research assistant for is that I can't be bothered, when I'm writing something, to do the full Chicago-style footnote if I'm already referencing an academic paper. So I'd just put the URL as the footnote and then hire a research assistant and say, “Go to this URL and change it into a Chicago-style citation. That's it.” Unfortunately, my research assistant on the hardback used early-days ChatGPT for that work. He did the whole thing, came back, everything looked perfect. I said, “Wow, amazing job.” It was only later, as I was going through them, that I realised something like 50% of them were invented footnotes. It was very painful to go back and fix, and it took ten times more time. With the paperback edition, I didn't use AI that much, but I did say things like, “Here's all the information – generate a Chicago-style citation.” That was better. I noticed there were a few things where I stopped using the thesaurus function on Microsoft Word because I'd just put the whole paragraph into the AI and say, “Give me ten other options for this one word,” and it would be like a contextual thesaurus. That was pretty good. Talking to a Robot Pianist Character Jamie: Then, for my new novel Virtuoso, I was writing a character who is a futurist robot that plays the piano very beautifully – not just humanly, but almost finding new things in the music we've written and composing music that resonates with us. I described the actions of that robot in the novel, but I didn't describe the inner workings of the robot's mind. In thinking about that character, I realised I was the first science-fiction writer in history who could interrogate a machine about what it was “thinking” in a particular context. I had the most beautiful conversations with ChatGPT, where I would give scenarios and ask, “What are you thinking? What are you feeling in this context?” It was all background for that character, but it was truly profound. Co-Authoring The AI Ten Commandments with GPT-5 Jamie: Third, I have another book coming out in May in the United States. I gave a talk this summer at the Chautauqua Institution in upstate New York about AI and spirituality. I talked about the history of our human relationship with our technology, about how all our religious and spiritual traditions have deep technological underpinnings – certainly our Abrahamic religions are deeply connected to farming, and Protestantism to the printing press. Then I had a section about the role of AI in generating moral codes that would resonate with humans. Everybody went nuts for this talk, and I thought, “I think I'm going to write a book.” I decided to write it differently, with GPT-5 as my named co-author. The first thing I did was outline the entire book based on the talk, which I'd already spent a huge amount of time thinking about and organising. Then I did a full outline of the arguments and structures. Then I trained GPT-5 on my writing style. The way I did it – which I fully describe in the introduction to the book – was that I'd handle all the framing: the full introduction, the argument, the structure. But if there was a section where, for a few paragraphs, I was summarising a huge field of data, even something I knew well, I'd give GPT-5 the intro sentence and say, “In my writing style, prepare four paragraphs on this.” For example, I might write: “AI has the potential to see us humans like we humans see ant colonies.” Then I'd say, “Give me four paragraphs on the relationship between the individual and the collective in ant colonies.” I could have written those four paragraphs myself, but it would've taken a month to read the life's work of E.O. Wilson and then write them. GPT-5 wrote them in seconds or minutes, in its thinking mode. I'd then say, “It's not quite right – change this, change that,” and we'd go back and forth three or four times. Then I'd edit the whole thing and put it into the text. So this book that I could have written on my own in a year, I wrote a first draft of with GPT-5 as my named co-author in two days. The whole project will take about six months from start to finish, and I'm having massive human editing – multiple edits from me, plus a professional editor. It's not a magic AI button. But I feel strongly about listing GPT-5 as a co-author because I've written it differently than previous books. I'm a huge believer in the old-fashioned lone author struggling and suffering – that's in my novels, and in Virtuoso I explore that. But other forms are going to emerge, just like video games are a creative, artistic form deeply connected to technology. The novel hasn't been around forever – the current format is only a few centuries old – and forms are always changing. There are real opportunities for authors, and there will be so much crap flooding the market because everybody can write something and put it up on Amazon. But I think there will be a very special place for thoughtful human authors who have an idea of what humans do at our best, and who translate that into content other humans can enjoy. Traditional vs Indie: Why This Book Will Be Self-Published Jo: I'm interested – you mentioned that it's your named co-author. Is this book going through a traditional publisher, and what do they think about that? Or are you going to publish it yourself? Jamie: It's such a smart question. What I found quickly is that when you get to be an author later in your career, you have all the infrastructure – a track record, a fantastic agent, all of that. But there were two things that were really important to me here: I wanted to get this book out really fast – six months instead of a year and a half. It was essential to me to have GPT-5 listed as my co-author, because if it were just my name, I feel like it would be dishonest. Readers who are used to reading my books – I didn't want to present something different than what it was. I spoke with my agent, who I absolutely love, and she said that for this particular project it was going to be really hard in traditional publishing. So I did a huge amount of research, because I'd never done anything in the self-publishing world before. I looked at different models. There was one hybrid model that's basically the same as traditional, but you pay for the things the publisher would normally pay for. I ended up not doing that. Instead, I decided on a self-publishing route where I disaggregated the publishing process. I found three teams: one for producing the book, one for getting the book out into the world, and a smaller one for the audiobook. I still believe in traditional publishing – there's a lot of wonderful human value-add. But some works just don't lend themselves to traditional publishing. For this book, which is called The AI Ten Commandments, that's the path I've chosen. Jo: And when's that out? I think people will be interested. Jamie: April 26th. Those of us used to traditional publishing think, “I've finished the book, sold the proposal, it'll be out any day now,” and then it can be a year and a half. It's frustrating. With this, the process can be much faster because it's possible to control more of the variables. But the key – as I was saying – is to make sure it's as good a book as everything else you've written. It's great to speed up, but you don't want to compromise on quality. The Coming Flood of Excellent AI-Generated Work Jo: Yeah, absolutely. We're almost out of time, but I want to come back to your “flood of crap” and the “AI slop” idea that's going around. Because you are working with GPT-5 – and I do as well, and I work with Claude and Gemini – and right now there are still issues. Like you said about referencing, there are still hallucinations, though fewer. But fast-forward two, five years: it's not a flood of crap. It's a flood of excellent. It's a flood of stuff that's better than us. Jamie: We're humans. It's better than us in certain ways. If you have farm machinery, it's better than us at certain aspects of farming. I'm a true humanist. I think there will be lots of things machines do better than us, but there will be tons of things we do better than them. There's a reason humans still care about chess, even though machines can beat humans at chess. Some people are saying things I fully disagree with, like this concept of AGI – artificial general intelligence – where machines do everything better than humans. I've summarised my position in seven letters: “AGI is BS.” The only way you can believe in AGI in that sense is if your concept of what a human is and what a human mind is is so narrow that you think it's just a narrow range of analytical skills. We are so much more than that. Humans represent almost four billion years of embodied evolution. There's so much about ourselves that we don't know. As incredible as these machines are and will become, there will always be wonderful things humans can do that are different from machines. What I always tell people is: whatever you're doing, don't be a second-rate machine. Be a first-rate human. If you're doing something and a machine is doing that thing much better than you, then shift to something where your unique capacities as a human give you the opportunity to do something better. So yes, I totally agree that the quality of AI-generated stuff will get better. But I think the most creative and successful humans will be the ones who say, “I recognise that this is creating new opportunities, and I'm going to insert my core humanity to do something magical and new.” People are “othering” these technologies, but the technologies themselves are magnificent human-generated artefacts. They're not alien UFOs that landed here. It's a scary moment for creatives, no doubt, because there are things all of us did in the past that machines can now do really well. But this is the moment where the most creative people ask themselves, “What does it mean for me to be a great human?” The pat answers won't apply. In my Virtuoso novel I explore that a lot. The idea that “machines don't do creativity” – they will do incredible creativity; it just won't be exactly human creativity. We will be potentially huge beneficiaries of these capabilities, but we really have to believe in and invest in the magic of our core humanity. Where to Find Jamie and His Books Jo: Brilliant. So where can people find you and your books online? Jamie: Thank you so much for asking. My website is jamiemetzl.com – and my books are available everywhere. Jo: Fantastic. Thanks so much for your time, Jamie. That was great. Jamie: Thank you, Joanna.The post Writing The Future, And Being More Human In An Age of AI With Jamie Metzl first appeared on The Creative Penn.

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Dr. Melissa Ilardo, Ph.D is a professor of evolutionary genomics and biomedical informatics at the University of Utah. Her research explores human evolution and adaptation in populations that have previously been overlooked or excluded from biological research. Her recent work looks into a population who engages in the practice of breath-hold diving & is evolving on a unique breakaway trajectory from the rest of homo sapiens on earth. SPONSORS https://hellofresh.com/danny10fm - Get 10 Free Meals + a Free breakfast for Life! https://cell.ver.so/danny - Use code DANNY to save 15% on your first order. https://butcherbox.com/danny - Get free steak in every box for a year PLUS $20 off your first box. https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off EPISODE LINKS https://medicine.utah.edu/faculty/melissa-ilardo https://www.superhumanlab.org https://www.nytimes.com/2018/04/19/science/bajau-evolution-ocean-diving.html https://www.instagram.com/superhumanscilab https://linkedin.com/in/melissa-ilardo FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Genomic evolution of Baju people (sea nomads) 15:00 - How long Baju can hold their breath for 21:19 - All-female Korean free divers (Haenyeo) 32:17 - Lost species of humans 42:44 - Humans won't survive the next 100,000 years 47:50 - Mother of humanity: The real "Eve" 59:48 - Humans are attracted to mates by pheromones 01:06:30 - Why assisted reproductive technology might be harmful to evolution 01:14:57 - Effects of the global population mixing & mating together 01:21:37 - Risks of CRISPR gene editing 01:30:37 - Lifespan & the grandmother hypothesis 01:37:18 - Evolution of un-contacted indigenous tribes 01:40:50 - What future humans will look like 01:49:08 - Intelligence is not genetic Learn more about your ad choices. Visit podcastchoices.com/adchoices

New weight loss drugs may portend end of “Fat Acceptance” movement; Celebs and Southerners embrace GLP-1s; Trump clears path for more access to diet drugs; Mid- and late-life exercise slash dementia risk; “Ethicists” urge more tick-borne meat allergy to save planet—as alpha-gal syndrome claims first fatality; What's wrong with the melatonin study that claims it leads to heart failure? How to detox 9-11 first-responders? Can weekend warriors obtain same benefits as regular exercisers? 

Broadcast from KSQD, Santa Cruz on 11-20-2025: Dr. Dawn discusses GLP-1 inhibitors like Zepbound and semaglutide showing unexpected benefits for addiction treatment beyond diabetes and weight loss. Patients in rehab report these drugs mute cravings for alcohol, cocaine, and cigarettes. Multiple studies show reduced substance abuse rates in users, with VA and NIH conducting trials examining brain activity and responses to triggers. With 80,000 annual drug overdose deaths and 48 million Americans having substance abuse disorders, these medications may revolutionize addiction treatment by dampening brain reward circuitry, though costs threaten healthcare budgets. A Stanford twin study found those twins assigned a vegan diet had substantially lower cholesterol, insulin, and body weight compared to their omnivore twins after several months, with LDL dropping 15mg, four pounds more weight loss, and 20% lower insulin. Dr. Dawn explains how a fungal disease decimating Central American frog populations caused 500% malaria increases in some areas. The fungus kills frogs by blocking skin electrolytes until hearts stop, eliminating tadpoles that eat mosquito larvae. Ecosystem collapses followed with algae blooms and snake population drops. She provides other examples showing how species losses affect human health, emphasizing the "one health" movement recognizing ecosystem health as fundamental to human wellbeing. An Australian study found people aged 70+ who listen to or play music regularly had 39% lower dementia rates, though causation remains uncertain. Princeton research shows music activates multiple brain regions simultaneously. Learning instruments increases gray matter, and musical memory remains intact in advanced dementia since it's stored separately from other memories. A caller discusses how modern screen-based activities provide less multisensory engagement than past social experiences like dances. Another caller describes Grover's disease causing persistent itchy skin with no known cause. Dr. Dawn recommends an elimination diet removing common allergens for one month, then reintroducing individually to identify food sensitivities triggering immune responses. Dr. Dawn explains xenotransplantation advances with genetically edited pigs beginning full-scale kidney transplant trials. Companies use CRISPR to disable genes causing immune rejection and insert human genes promoting immune tolerance. With only 10% of global kidney patients receiving organs, these could provide unlimited supply. Other innovations include kidneys with thymus tissue to teach immune tolerance and external pig liver systems as transplant bridges. She concludes noting research showing female dogs remember and prefer humans who demonstrate competence at tasks, while male dogs show no preference.

A recent study explored the emerging role of KCNQ5 potassium channels in vascular smooth muscle regulation and their potential as therapeutic targets to promote vasodilation and manage blood pressure. Hear from Dr. Geoffrey Abbott as he dives into cutting-edge research using a CRISPR-generated KCNQ5 knockout rat model, revealing critical insights into adrenergic signaling, vascular reactivity, and the vascular effects of aloperine. Dr. Abbott is a Professor and Interim Chair of Physiology and Biophysics at the UC Irvine School of Medicine, and he also spoke about this topic at the 2025 American Heart Association Scientific Sessions.

Angel Studios https://Angel.com/Herman Join the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar Today 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeIt's All One Thing: US Catholic Bishops and Treason Demanding Democrats // Are You Ready for GMO Babies?  // To The Progressive Church, Satan is a Christian.Episode links:Democrats Demand Our Military Members Revolt Against The President.Special Pastoral Message on Immigration by the Bishops of the United StatesCam Higby just CALLED OUT the mayor of Muslim-dominated Dearborn Michigan at the council meetingOpenAI CEO Sam Altman and His Husband Are Funding the Creation of Genetically Engineered Babies; The rebirth of Frankenstein in the era of CRISPR and AI Elon Musk on how Optimus will provide access to the best medical care for anyone in the world:Poll: 4 In 5 Americans Are ‘Concerned' About Silicon Valley's Unregulated Embryo-Screening SchemeGene-Editing Human Embryos: A Doomed Technological Catastrophe; Epidemiologist Nicolas Hulscher on Real America's Voice  Blaire White professes to be Christian:

This episode is a double from my visit to the Advanced Lateral Flow Conference. Usability is Innovation: Atomo DiagnosticsAtomo Diagnostics set out more than a decade ago to solve a surprisingly human problem in diagnostics: complexity. Founder John Kelly describes how even the best rapid tests—validated in pristine lab environments—often fail when they reach the real world, where people have no training, and shaky instructions. That gap between laboratory precision and real-world usability has huge implications for reliability, trust, and ultimately regulatory approval.Atomo's core insight is simple: most errors in point-of-care testing aren't biological—they're behavioral. The accessories people use in the field (cheap pipettes, dropper bottles, uncalibrated parts) invite mistakes, and the more steps required, the higher the failure rate. Kelly and his team approached the problem the way a designer might: observe how real users behave, then engineer around human nature instead of fighting it.To validate their approach, they went straight to the source—literally to the community—conducting studies in Africa with low-literacy users who received only picture-based instructions. “If it needs a lot of explanation, it's probably not obvious,” Kelly notes. The goal: build a device that is self-explanatory and self-correcting.Their solution, the Pascal platform, integrates every accessory needed to run a test—lancet, blood collection, and buffer reagent—directly into one cartridge. Instead of multiple steps and parts, users simply collect, press, and go. Each step is interlocked to prevent mistakes; for instance, the reagent button won't activate until blood is correctly loaded. It's engineering that enforces proper sequence, eliminating user doubt and waste.Kelly describes how this design delivers the right volume, in the right order, every time—removing the “what if I did it wrong?” anxiety that undermines confidence in results. It's the difference between a reliable diagnostic and a false sense of security.Atomo's HIV self-test—registered with the World Health Organization and distributed across Australia, Europe, and the UK—has demonstrated greater than 99% concordance between trained and untrained users. The company also supports a blood-based pregnancy test (approved in Europe and Brazil) that detects earlier than urine tests, and they're now developing the world's first active syphilis test, capable of distinguishing between current and previously treated infections.What's equally smart is their business model flexibility. Recognizing that many manufacturers already have validated lateral flow cassettes on the market, Atomo developed a “clip-on” usability upgrade that integrates their collection and buffer technology without requiring full retooling or revalidation—a bridge between old workflows and modern design.Beyond infectious disease, Kelly sees growth in at-home wellness and chronic condition monitoring—everything from testosterone and thyroid tests to celiac screening. The platform's adaptability makes it attractive for home use and clinical trials alike. One example: a pharmaceutical partner using Atomo's device to monitor liver toxicity in patients remotely, reducing clinic visits from three times a week to “only when needed.” It's better for patients, cheaper for healthcare systems, and faster for research.The bigger story here is that usability is innovation. Kelly's approach turns workflow design into a driver of impact. Instead of chasing exotic chemistry, Atomo focused on reliability and trust—two things that ultimately decide whether a test makes it into people's hands.As diagnostics and healthcare move increasingly into the home, Atomo's design philosophy feels ahead of its time. If the pandemic taught us anything, it's that people can and will take responsibility for their health—if we give them tools that make sense.Pitch Competition Finalist: EAZEBIOI also sat down with Ying Chen, founder of EAZEBIO, one of the Innovation Award finalists. Her company's portable strip-based diagnostic platform combines CRISPR and AI to bring precision health to everyone, especially in low-resource settings.The Problem: Reactive HealthcareYing opens by explaining the fundamental flaw she sees in today's healthcare system—it's reactive. We wait for symptoms to become severe before acting. EAZEBIO's mission is to shift the paradigm toward proactive, precision healthcare, emphasizing early detection and personalized intervention. Her team focuses on diseases often overlooked at the root-cause level—metabolic, autoimmune, and cardiovascular conditions.Their aim is to bridge the gap between scientific breakthroughs and universal access, translating biomarker data into actionable health insights. As Ying puts it, “We hope proactive, personalized care can provide health equity for everyone, no matter where they live.”Ying's background is a blend of pediatrics, research science, and business—she holds both a PhD and an MBA. Her experience inspired her to adapt the power of CRISPR from the lab to the home.In their prototype for sepsis detection, EAZYBIO's system uses CRISPR to identify antimicrobial resistance genes—the genetic clues that reveal which pathogen is causing an infection. The test also detects human protein biomarkers, providing a two-layered view of infection and host response.Here's how it works:* The CRISPR complex acts like a molecular “scissor,” recognizing and cutting specific DNA or RNA sequences associated with infection.* These sequences are tagged with a cortisol-based reporter. When the CRISPR cut happens, cortisol is released.* The released cortisol binds to split reporter proteins, generating a visible signal on a lateral flow strip.* An AI-powered app then reads and interprets the signal into a semi-quantitative result.This approach achieves roughly 300x signal amplification compared to conventional lateral flow assays—crucial for fast, reliable results.Sepsis is notoriously time-sensitive; treatment delays of more than three hours can dramatically increase mortality. Ying emphasizes that EAZEBIO's platform could enable clinicians to identify pathogens and select the correct antibiotic within one hour—a potentially life-saving improvement.While sepsis is their initial target, the underlying platform is modular and scalable, enabling future multiplexing for 3–5 pathogens per test. Beyond acute disease, the same technology could support early cancer detection and wellness testing, making high-quality diagnostics as easy as a home pregnancy test.Ying speaks with humility about being a finalist at ALFC, but it's clear the recognition validates EAZEBIO's bold vision. The conference gave her valuable exposure to peers across R&D and manufacturing, as well as insights into where diagnostics are heading over the next decade.Her takeaway? Collaboration and accessibility matter just as much as innovation. “It's not just technology—it's about bringing care to everyone, whether they live in a big city or a rural village.” This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit cclifescience.substack.com

Angel Studios https://Angel.com/Herman Join the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar THIS Thursday 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeMarjorie Taylor Greene: Lying or Repenting? // The Epstein Connection to Sam Altman's Gene-Editing of Babies // On Ben Shapiro's Million Dollars to a Christian Group… Episode Links:Raskin: We are a big tent. We must be a huge, vast tent. I say this is a party that's got room for Marjorie Taylor Greene if she wants to come over.JFK's grandson Jack Schlossberg: "President Trump is so obsessed with the Kennedys and the Kennedy name that he caged one and put in his cabinet— a rabid dog in his cabinet. Put a collar on my cousin RFK Jr and has him there barking, spreading lies and misinformation."An illegal alien attacked a woman with a hammer while she was out jogging in Plano, Texas, Thursday. The victim fought back even after being struck twice, causing the 17-year-old attacker, Sergio Noe De Nova Duarte, to flee the scene. Fox & Friends: “The 17-year-old suspect was quickly arrested. Police say when his fingerprints were processed, they received a notification to place him under an ICE hold.” “So far, he's been charged with aggravated kidnapping with bodily injury and is now being held by ICE.”MTG just took full ownership on CNN and it's one of the most unexpected moments of the year. When asked why she only denounced Trump's rhetoric after it was directed at her, she didn't deflect. She owned it: “That's fair criticism… and I would like to say humbly, I'm sorry for taking part in the toxic politics. It's very bad for our country.”Elon Musk on how Optimus will provide access to the best medical care for anyone in the world:OpenAI CEO Sam Altman and His Husband Are Funding the Creation of Genetically Engineered Babies; The rebirth of Frankenstein in the era of CRISPR and AILarry Summers steps back from public roles after House release of Epstein correspondenceFormer Harvard president says he's 'deeply ashamed' of continued communication with disgraced financierBen Shapiro donated $1M to TPUSA to help "bring people back to Christ, and bring people back to church, and back to biblical values," as Charlie wanted. The nonstop slander against him is clearly well-funded and highly organized.According to Ben Shapiro himself, Jesus was a "bad guy" who tried to overthrow the Roman Empire and was killed for "his troubles." - "I don't believe in the Jesus."Do non-Jews or non-Noahides go to heaven?What Are the Seven Noahide Laws?

In this special episode of Robin's Nest, we're joined by Dr. George Church, a world-renowned geneticist and one of the leading minds behind the Human Genome Project, for a conversation about the amazing ways science is helping us understand, protect and even restore life on Earth.Dr. Church takes us inside the frontier of synthetic biology, from the origins of CRISPR and gene editing to the bold promise of de-extinction, conservation technology and genetic equity. The discussion spans his groundbreaking work with Colossal Biosciences, where efforts to revive the woolly mammoth and other lost species aim to restore ecosystems and rethink what “saving nature” means in the 21st century.Listeners will hear Dr. Church reflect on the ethics and responsibilities of rewriting life's code, the potential for genetic engineering to combat biodiversity loss, and why he believes “extinction doesn't have to be forever.” This episode explores how technology and conservation can work hand-in-hand to heal the planet.A fascinating journey into the science shaping our shared future, and a reminder that innovation, guided by compassion and curiosity, may yet help us write a better story for life on Earth.

Broadcast from KSQD, Santa Cruz on 11-13-2025: Dr. Dawn discusses a New England Journal of Medicine study examining radiation exposure from medical imaging in over 4 million children showing increased hematological cancer risk. Head and brain CTs deliver highest bone marrow doses, with under-1-year-olds receiving 20 milligrays compared to background radiation of 1 milligray yearly. The study found 3,000 cancers in 4 million children over roughly 10 years, with relative risk increasing 1.6-fold per CT scan. However, methodological flaws include combining US and Canadian cohorts with different data quality, potential reverse causation where imaging detected pre-existing cancers, and arbitrary 6-month latency assumptions are significant flaws in this study.. Despite small absolute risk increases given low baseline cancer rates, she encourages parents to question necessity of repeat scans and request alternatives like MRI when appropriate. She reports on cutting-edge CRISPR therapy using lipid nanoparticles to deliver molecular scissors targeting the ANGPTL3 gene controlling LDL cholesterol production. Recent setbacks in several other CRISPR trials raise issues for unexplained liver toxicity. Concerns include off-target gene editing effects and partially repaired DNA creating mutated proteins triggering autoimmune reactions. Dr. Dawn emphasizes restricting gene therapy to life-threatening genetic diseases with no alternatives until safety improves. Stanford scientists used AI model Evo trained on 9 trillion gene samples to design 300 new bacteriophages from scratch, with 16 phages successfully killing E. coli bacteria. AI tools now predict protein structures, design custom drugs, create antivenoms, invent antibiotics, and break down PFAS forever chemicals. The research represents evolution through computation and requires guardrails on AI's ability to manipulate biological structures. An emailer shares the Rosencare model where hotel chain owner Harris Rosen created self-insured health coverage featuring direct provider contracting, imaging facilities charging one-third to one-half traditional costs, transparent pharmacy benefit management, and zero or $5 primary care copays. Employees receive proactive screening for colonoscopies, mammograms, cholesterol, diabetes, and hypertension during clinic visits. Ninety percent of medicines including insulin cost nothing, with remaining drugs $0-25, and hospital admissions cost flat $750. The model saved $600 million while providing superior preventive care by eliminating insurance middlemen and focusing on early chronic disease detection when 75-85% of costs originate. Dr. Dawn explains abdominophrenic dyssynergia causing bloating unrelated to gas or food. The diaphragm descends and abdominal wall muscles relax, pushing organs forward after meals. CT scans showed lettuce-related bloating involved no intestinal gas changes but demonstrated this abnormal muscle reflex. Randomized trials showed biofeedback training with chest-lifting and abdominal wall contracting exercises before and after eating for four weeks improved symptoms 66%. She warns that constant bloating in postmenopausal women unrelated to eating requires ovarian cancer screening. She discusses how genes drive personality using dopamine receptor gene DRD4 polymorphisms as an example. The 7-repeat variant present in 48% of Americans creates receptors binding dopamine poorly, associating with ADHD, pathological gambling, alcoholism, drug dependence, and bulimia, plus personality traits of novelty-seeking, impulsiveness, and optimism. The 2-repeat DRD4 variant common in Asia correlates with lower anger and higher forgiveness. DRD2 variations enhance the memory of negative outcomes, creating pessimistic bias and avoidance behavior. She presents the KETO trial showing "lean mass hyper-responder phenotype" where very low-carbohydrate dieters averaging age 55 maintained LDL cholesterol of 272 for five years but showed identical coronary artery calcium scores and plaque burden as matched controls with LDL under 150. Despite extreme LDL elevation, the very low insulin levels from carbohydrate restriction prevent LDL oxidation, the inflammatory "loading" process enabling arterial damage. She concludes with unusual cancer symptom where recurrent pain in specific body locations after alcohol consumption, lasting 1-2 days, occurs in 5% of Hodgkin lymphoma patients and in other cancers when alcohol induced blood vessel dilation and inflammatory chemical release in cancer-containing lymph nodes causes pain after drinking.

On this week's episode, John Maraganore, Yaron Werber, Ami Fadia, and special guests STAT's Allison DeAngelis and Endpoints News' Drew Armstrong kick things off with an overview of the latest FDA staffing changes, including long-time oncology chief Richard Pazdur's appointment as the new CDER director, a move the co-hosts view as positive for the industry and a sign of potential stability. Next, the group breaks down the FDA's new ‘Plausible Mechanism Pathway', designed to accelerate certain personalized therapies to market when traditional trials aren't feasible. Allison then shares insights from her reporting on the exclusive MAHA Summit held earlier this week -- an invite-only gathering of top HHS officials and leading biotech executives. In data news, the co-hosts discuss Alkermes' Phase 2 narcolepsy trial, Cogent's Phase 3 gastrointestinal stromal tumor results, and CRISPR's cholesterol data. As one bidding war ends, another begins as Alkermes' move to acquire Avadel faces competition from Lundbeck, who offered a $2.25 billion, rivaling Alkermes' initial $2.1 billion offer. Drew Armstrong also overviewed his reporting on the Novo Nordisk-Pfizer bidding war, noting both companies' obesity setbacks and their search for new directions. Deal-making conversations continues with Merck's $9.2 billion acquisition of Cidara Therapeutics, and Day One Therapeutics' $285 million acquisition of Mersana Therapeutics. The episode concludes with a discussion on the passing of genetic pioneer James Watson and Eli Lilly CEO David Ricks' appearance on The Cheeky Pint podcast. *This episode aired on November 14, 2025.

TUCKER PLAYS THE HAARP - 11.12.2025 - #891 BestPodcastintheMetaverse.com Canary Cry News Talk #891 - 11.12.2025 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com   Join the Canary Cry Roundtable This Episode was Produced By:   Executive Producers LX Protocol BARON of the Berrean Protocol*** Sir Jamey Not the Lanister***   Producers of TREASURE (CanaryCry.Support) Mark T, Mrs TinFoilHatMan, Veronica D, Sir Scott Knight of Truth, Sir Casey the Shield Knight   Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM     MONEY 5:40 Last penny ever minted today in Philadelphia    BIBLICAL 48:55 The U.S. saw vivid northern lights as far south as Florida — and more could be coming (NPR) → Northern Lights over America (X)    GEOENGINEERING 51:54 Dane Wigington on Tucker Carlson (huffpo) Dane wigington on newsmax Dane Wigington on Canary Cry Radio   DNA 1:30:50 Startup Secretly Working to Gene-Hack Human Baby (Futurism) → US baby receives first-ever customized CRISPR treatment (March 2025, Live Science)   ECONOMIST COVER 2:02:42 The Economist Group - The Economist launches The World Ahead 2026–with rich countries living beyond their means, the risk of a bond-market crisis is growing   TRUMP/EPSTEIN  New Epstein Emails Alleged Trump Knew of His Conduct (NY Times) released Epstien emails Fishy (X)   AI/BEAST SYSTEM 2:08:24 Woman marries AI character she made on ChatGPT after real marriage gets called off (Dextero)   FLIPPY UPDATE Global Robot Arms Market to Reach USD 36.2 Billion by 2035, Driven by Precision Automation and Smart Manufacturing Integration, Reports Fact.MR (Open PR)   EXECUTIVE PRODUCERS TALENT/TIME END

Howie and Harlan are joined by Harvard internist Jerry Avorn to discuss his research on the pharmaceutical industry and his work promoting evidence-based prescribing. Harlan highlights new results from the American Heart Association meeting, including a one-time CRISPR-based therapy for high cholesterol; Howie reports on an outbreak of infant botulism. Show notes: Research from the American Heart Association Meeting "Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3" "First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides" "Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial" "PCSK9 medication plus statin may help lower cholesterol after heart transplant" "Investigational daily pill lowered bad cholesterol as much as injectables" Jerry Avorn Science Direct: Academic Detailing Jerry Avorn: "Principles of Educational Outreach ('Academic Detailing') to Improve Clinical Decision Making" Alosa Health FDA: Accelerated Approval Jerry Avorn: Rethinking Medications: Truth, Power, and the Drugs You Take FDA: Direct-to-Consumer (DTC) Advertisements H.R.5952 - Prescription Drug User Fee Act of 1992 FDA: FY 2025 FDA Budget Summary Centers for Medicare & Medicaid Services: Open Payments  H.R.3590 - Patient Protection and Affordable Care Act "Aducanumab Discontinued as an Alzheimer's Treatment" FDA: ELEVIDYS Brigham and Women's Hospital & Harvard Medical School: Division of Pharmacoepidemiology and Pharmacoeconomics Amazon.com: Featured comments on Rethinking Medications Infant Botulism California Department of Public Health: "Outbreak of Infant Botulism Linked to ByHeart Infant Formula" California Department of Public Health: Infant Botulism Treatment and Prevention Program CDC: "Infant Botulism Outbreak Linked to Infant Formula, November 2025" "ByHeart recalls all baby formula sold nationwide as infant botulism outbreak grows" California Department of Public Health: What is BabyBIG? California Department of Public Health: Postponement of BabyBIG Fee Increase California Department Of Public Health: Invoice and Purchase Agreement for BabyBIG In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.  

This week on Lost in Science Stu checks in on the cutting edge of CRISPR — the revolutionary gene-editing technology promising to change how we treat diseases. Is it living up to the hype? And as we head into the holiday season, Chris is getting practical with physics, applying maths and motion to the age-old problem of how to pack your bag efficiently.

Consumer insights guru Liz Sloan unpacks the latest consumer demographic trends and how they will shape food and beverage market opportunities. Tom Adams, CEO of Pairwise, discusses the potential of the gene-editing technology CRISPR to advance agriculture and deliver better-tasting fruits and vegetables.   Plus: This episode of Omnivore is brought to you by CoDeveloper, from IFT. CoDeveloper is the first AI-powered co-scientist built BY food scientists FOR food scientists, … Continue reading EP 71: Understanding the New Mainstream Consumer, Gene Editing Tomorrow's Crops →

TWiP discusses a 41-year long human infection with Schistosoma mansoni, and CRISPR screens that reveal genes essential for Cryptosporidium survival in the host intestine. Hosts: Vincent Racaniello, Daniel Griffin, and Christina Naula Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Links for this episode Join the MicrobeTV Discord server 41 year old Schistosoma infection (J Travel Med) Genes essential for Cryptosporidium survival in host intestine (Nat Comm) Become a patron of TWiP  Send your questions and comments to twip@microbe.tv Music by Ronald Jenkees

Likely you have not spent a lot of time reading Ephraim the Syriac. What does he have to do with end times prophecies? Pastor Gene Pensiero Find audio, video, and text of hundreds of other prophecy updates at: https://calvaryhanford.com/prophecy Read along with us at https://calvaryhanford.substack.com Follow us on YouTube at https://youtube.com/calvaryhanford — Prophecy Unsealed: Early […]

V tokratni Frekvenci X se pogovarjamo z nesojenim nobelovcem, litovskim znanstvenikom Virginijusom Šikšnysom. Bil je eden prvih, ki je ugotovil mehanizem sistema CRISPR. Spoznali smo njegovo zgodbo in smolo z objavo članka ter se z dr. Romanom Jeralo s Kemijskega inštituta spraševali, kako težko je doseči objavo v pomembnih znanstvenih revijah, če prihajaš iz malega inštituta majhne evropske države, kot je Litva. In nenazadnje tudi Slovenija. Poglavja: 00:21:20 Xpertiza: Domen Vreš

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of groundbreaking advancements and strategic collaborations that promise to transform drug development and patient care.In the autoimmune space, Boehringer Ingelheim has made a significant move by securing a $570 million agreement with CDR-Life. This deal centers on a trispecific antibody, a novel therapeutic approach that targets multiple pathways simultaneously, potentially revolutionizing treatments for autoimmune diseases. Boehringer's commitment to these cutting-edge modalities highlights their strategy to leverage novel technologies for more effective therapeutic solutions.Similarly, Celltrion has entered a $744 million collaboration with Kaigene, focusing on two preclinical autoimmune drugs. This partnership marks Celltrion's strategic shift from biosimilars to novel biologics, positioning the company at the forefront of biologic therapeutics. By investing in early-stage research, Celltrion aims to introduce transformative therapies for autoimmune conditions, showcasing the industry's willingness to bet on groundbreaking scientific advancements.In gene editing, Azalea Therapeutics is gaining attention with its focus on permanent genome editing using a dual-vector approach. Backed by $82 million in funding and support from CRISPR pioneer Jennifer Doudna, Azalea is poised to develop potentially curative solutions through single-dose treatments. The credibility lent by a Nobel laureate adds anticipation to their research outcomes, with the potential to significantly impact gene therapy.Shifting focus to clinical trials, Sarepta Therapeutics faces challenges after missing the primary endpoint in its confirmatory trial for Duchenne muscular dystrophy drugs. Despite this setback, Sarepta is pursuing full FDA approval, emphasizing the complex interplay between clinical data and regulatory strategies. This situation underscores the critical importance of robust confirmatory trials in securing drug approvals and ensuring patient access to new therapies.Merck is making strategic moves in oncology by regaining full control over an early-phase asset and securing $700 million from Blackstone for its oncology pipeline. This dual focus on asset acquisition and financial fortification reflects Merck's aggressive growth strategy aimed at expanding its cancer treatment offerings.Emerging from stealth mode, Neok Bio has secured a $75 million investment to advance bispecific antibody-drug conjugates into clinical trials. These bispecific ADCs represent the forefront of targeted cancer therapies, aiming for precision targeting of cancer cells while minimizing off-target effects. Neok Bio's progress could significantly enhance oncology treatment paradigms through improved therapeutic indices.Turning to regulatory landscapes, Teva's recall of over half-a-million bottles of prazosin hydrochloride due to potential carcinogenic impurities highlights ongoing challenges in ensuring drug safety and quality control within manufacturing processes. Such recalls underscore the critical importance of maintaining high standards in pharmaceutical production.In broader industry developments, we see dynamic trends where scientific innovation meets strategic business decisions and regulatory considerations. The potential impact on patient care is profound, with breakthroughs in autoimmune treatments, gene editing technologies, and targeted cancer therapies poised to alter therapeutic landscapes significantly.UCB has achieved another milestone with FDA approval for Kygevvi, an ultra-rare disease medication marking their third approval in rare conditions within three years. This success underscores UCB's strategic focus on niche markets that offer less competition but significant patient impact. Advancements in genetic research aSupport the show

To Find Deplorable Janet--> https://open.spotify.com/show/3K5Xi9LugxNdI06GXSIjAp?si=m5hPD7OsS6eim1jACk84ewTo sign up for our Patreon go to-> Patreon.com/cultofconspiracypodcast To Join the Cajun Knight Patreon---> Patreon.com/cajunknight To Find The Cajun Knight Youtube Channel---> click hereTo Invest In Gold & Silver, CHECK OUT—-> Www.Cocsilver.com 10% OFF Rife Machine---> https://rifemachine.myshopify.com/?rfsn=7689156.6a9b5c To find the Meta Mysteries Podcast---> https://open.spotify.com/show/6IshwF6qc2iuqz3WTPz9Wv?si=3a32c8f730b34e79 50% OFF Adam&Eve products---> :adameve.com (promo code : CULT) To Sign up for our Rokfin go to --> Rokfin.com/cultofconspiracy Become a supporter of this podcast: https://www.spreaker.com/podcast/cult-of-conspiracy--5700337/support.

We've entered a new age. Where nature once took a million years to make a few genetic changes, scientists can now make billions in an afternoon — and even imagine adapting humans for life beyond Earth.George Church, a Harvard geneticist, pioneer of the Human Genome Project, and founder of more than 50 biotech companies, helped lay the foundation for CRISPR, personal genomics, and even de-extinction.In this episode, he explains how biotechnology, AI, and materials science are converging to transform life itself -  from reversing aging and curing disease to resurrecting lost species like the woolly mammoth, and one day, helping humanity thrive among the stars.

There's so much incredible research and work that happens every day at UC Berkeley, on everything from artificial intelligence and quantum computing to linguistics and the study of social justice. It holds the record for the most Nobel Prize winners among any public university in the world, with two wins just this year.This work can be highly theoretical and technical, taking decades to fully develop. Yet its impact extends far beyond academia, leading to world-changing results, from the invention of CRISPR gene editing that has saved lives to ethnic studies courses that foster a stronger sense of identity and critical consciousness. Within these broad impacts are millions of stories of how Berkeley's research has transformed society. In this season of Berkeley Voices, we hear two sides of a story — from Berkeley scholars working on life-changing research, and from the people who've been changed by it.New episodes will come out on the first Thursday of each month, from November through April. Listen to Berkeley Voices on your favorite podcast app or on YouTube @BerkeleyNews. You can find all of our podcast episodes, with transcripts and photos, on UC Berkeley News at news.berkeley.edu/podcasts.Listen to the episode and read the transcript on UC Berkeley News (news.berkeley.edu/podcasts/berkeley-voices).Music by Blue Dot Sessions.UC Berkeley design by Neil Freese. Hosted on Acast. See acast.com/privacy for more information.

This week, Brent speaks with Sir Adrian Bird, the pioneering geneticist whose discoveries on DNA methylation reshaped our understanding of how genes are regulated. Bird explains what DNA methylation actually is and why he's skeptical of popular claims that it determines "biological age" or can be easily hacked to reverse aging. They discuss his groundbreaking work on Rett syndrome, how CRISPR gene editing is being used in clinical trials to potentially cure it, and what that might mean for other neurological diseases. He's a wonderful guest. Hope you enjoy.

Grab your consent forms (but don't sign them yet) and your government-issued fetal monitoring bracelet, because today we're getting a broader understanding of what happens when people aren't treated like people but like data, vessels, and experiments. The body keeps the score- even when it's for medical horror stories. From Adriana Smith, kept alive against her will to serve as a human incubator under Georgia's abortion laws, to Henrietta Lacks, whose cells were stolen, immortalized, and monetized without her knowledge or family's consent, this episode unpacks the long, horrifying legacy of unethical medical research in America.We'll walk through the Tuskegee Syphilis Study, the Holmesburg Prison experiments, the HIV-tainted blood scandal that infected kids like Ryan White, while the government spent more money on the Tylenol murders than AIDS research. And this isn't ancient history, it's happening today- not just with Adriana Smith, or Terri Schiavo as a human prop before her but with forced sterilizations, CRISPR babies, and what happens when “the greater good” doesn't include you.This isn't an anti-science episode. I'm pro-science, but not when the most marganilzed among us have to die for it. And in a world where women, people of color, and the poor are still being used, sometimes even after death- it's more important than ever to ask:Who gets to be a patient? And who's just a test subject?(Originally released May 2025)Become a supporter of this podcast: https://www.spreaker.com/podcast/broads-next-door--5803223/support.

Emily is an Assistant Professor at MDI Biological Laboratory where she studies neurodegenerative disease-associated genes using super-resolution imaging of living, adult worms. Emily earned her Ph.D. at the University of Maine while embedded in the Jackson Laboratory and during her post-doc at MDI Bio Lab, she was recognized by the National Institutes of Health as an “Outstanding Scholar in Neuroscience”.This conversation was recorded in September 2025. ~~~~~The Maine Science Podcast is a production of the Maine Discovery Museum. It is recorded at Discovery Studios, at the Maine Discovery Museum, in Bangor, ME. The Maine Science Podcast is hosted and executive produced by Kate Dickerson; edited and produced by Scott Loiselle. The Discover Maine theme was composed and performed by Nick Parker. To support our work: https://www.mainediscoverymuseum.org/donate. Find us online:Maine Discovery MuseumMaine Discovery Museum on social media: Facebook Instagram LinkedIn Bluesky Maine Science Festival on social media: Facebook Instagram LinkedInMaine Science Podcast on social media: Facebook Instagram © 2025 Maine Discovery Museum

Krauter, Ralf www.deutschlandfunk.de, Forschung aktuell

Humans and nature have always coexisted. But, human intervention makes our modern world look very different than it once did. This episode, host Dr. Samantha Yammine digs into how humans are reshaping the wild. Sam speaks to Dr. Harland Patch about the decline of insect populations around the world and how we can provide better environments for pollinators. She also dives into the world of CRISPR gene editing among Argentinian polo horses and why so many people seem to be getting diagnosed with Lyme disease. Link to Show Notes HERE Follow Curiosity Weekly on your favorite podcast app to get smarter with Dr. Samantha Yammine — for free! Still curious? Get science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

In questa nuova puntata non possiamo non cominciare ringraziando gli ascoltatori che sono venuti a trovarci nella grigia Ginevra per una giornata con visita al CERN, alla città, e tradizioni culinarie a base di latticini! C'è chi dice che sia stata una bellissima giornata e c'è chi mente.Tornando alla scienza si realizza finalmente il sogno di Valeria, perché la puntata si apre con Francesca che parla di virus! Un nuovo preprint pubblicato dai ricercatori di Stanford ha sfruttato l'intelligenza artificiale per progettare nuovi batteriofagi in grado di infettare uno specifico ceppo di E. Coli. Diversi fagi sono stati sintetizzati e sono risultati infettivi e specifici! Nell'attesa che l'articolo sia pubblicato, questa potrebbe essere una nuova frontiera per la terapia fagica che è una delle armi a disposizione per combattere la resistenza agli antibiotici.Leonardo in esterna intervista Marco Giordani, professore di telecomunicazioni all'Università di Padova che ci spiega alcune sfide tecnologiche dietro alle moderne reti satellitari, continuando l'approfondimento iniziato la scorsa settimana.Tornati in studio, dopo una barza statisticamente brutta, Valeria ci parla di un nuovo articolo pubblicato su Nature, in cui viene identificato un nuovo recettore per TBEV, il virus dell'encefalite da zecche. Questa proteina, chiamata LRP8, è necessaria al virus per entrare nelle cellule ed è presente nelle cellule del sistema nervoso. I ricercatori, dopo aver verificato l'interazione specifica tra il virus e la proteina, hanno anche sviluppato una forma di recettore solubile che è capace di legarsi al virus e prevenire l'infezione nelle cellule e anche nei topi.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/scientificast-la-scienza-come-non-l-hai-mai-sentita--1762253/support.

Imaginez la scène : un poisson préhistorique, il y a des centaines de millions d'années. À cette époque, pas de doigts, pas de mains, juste des nageoires. Et pourtant, selon une étude publiée le 17 septembre 2025 dans la revue Nature, c'est dans cette créature aquatique qu'il faut chercher l'origine… de nos doigts. Et, encore plus étonnant, le secret se cache dans un organe qu'on n'aurait jamais soupçonné : son anus, ou plutôt son cloaca, cette ouverture unique qui servait à la fois à digérer, à uriner et à se reproduire.L'étude a révélé quelque chose de fascinant. Les chercheurs ont identifié un ensemble de séquences génétiques appelées “paysages régulateurs”. Ces petites régions d'ADN ne fabriquent pas de protéines, mais elles contrôlent l'activité de gènes essentiels. Parmi eux, les gènes Hox, qui orchestrent le développement du corps chez l'embryon. Or, chez les poissons, ce fameux paysage régulateur n'était pas du tout lié aux nageoires. Il était actif dans la formation du cloaca.Avec l'outil CRISPR, les scientifiques ont fait une expérience cruciale. Quand ils suppriment ce paysage régulateur chez la souris, les doigts et les orteils ne se forment pas correctement. Mais quand ils le suppriment chez un poisson, les nageoires se développent normalement… tandis que le cloaca, lui, est gravement perturbé. Autrement dit, la machinerie génétique qui a servi à construire nos doigts venait à l'origine d'un système utilisé pour bâtir un orifice digestif.C'est un exemple parfait de ce que les biologistes appellent la co-option évolutive. L'évolution n'invente pas à partir de rien. Elle réutilise des circuits anciens, elle détourne des mécanismes existants pour leur donner une nouvelle fonction. Dans ce cas, un “programme génétique” d'abord destiné au cloaca a été recyclé pour façonner des doigts lorsque nos ancêtres ont quitté l'eau pour marcher sur la terre ferme.Alors, quand vous bougez vos mains ou quand vous pianotez sur un clavier, souvenez-vous que ce geste quotidien porte la trace d'une histoire bien plus ancienne qu'on ne l'imagine. Vos doigts ne sont pas seulement les héritiers des nageoires d'un poisson, mais aussi le fruit d'un bricolage génétique qui, il y a très longtemps, concernait… un anus préhistorique. Voilà une image inattendue, presque poétique, qui nous rappelle à quel point l'évolution sait transformer le trivial en extraordinaire. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Lords: * Danny * https://nightbrunchband.com/ * Walker * https://nightbrunchband.com/ Topics: * You Probably Think This Song is About You * The Perfect r/crappymusic Post: An audio tour of Archetypes * https://media24.fireside.fm/file/fireside-uploads-2024/images/3/3597ddeb-e52e-4cda-a59c-c64600489fea/0291r0zf.png * https://www.youtube.com/watch?v=6EIwP0zerbk * Sample-based film scores in the 80s * https://www.tumblr.com/mogwaipoet/786937779224461312/terminator-2-1991-and-the-princess-bride-1987 * Do Not Stand at My Grave and Weep, by Clare Harner actually * https://en.wikipedia.org/wiki/DoNotStandatMyGraveand_Weep * Being a Video Game Newb in Your 40s Microtopics: * Is it a Topic or is it Just Banter? * Cleaning Lords, Lunch Lords and Cat Lords. * Have you heard the good word about the Gaylady? * Night Brunch. * Wearing your own band's t-shirt. * A thing that could happen for a while and then was no longer able to happen. * Hi Cindy! * Motivating yourself to work harder via self loathing. * Feeling the need to act all angsty so that people take you seriously as an artist. * A Touch of Grandiosity. * How many tracks get uploaded to SoundCloud every day? * Continuing to discover music from the 1970s. * It's called "Topic Lords," not "Correct Lords." * Once it becomes impossible to make new music, and we go back and start listening to all the SoundCloud uploads with 0 listens. * All the kids at Rock & Roll Camp getting excited about Lofey. * Pretending a topic is about one thing when it's actually about something else. * Canadian Actor Dave Coulier. * Tuesday at 3:01pm. * Learning a new chord on your Electric Tenor Guitar. * Bringing Pokemon Puzzle League characters into your love song. * Having a whole week to dial in that wub wub patch. * What art is for and what art should be for. * Fun is our only reward. * The objective best pitch wheel range. * The Funky Worm preset. * Synthesizers that can save and load patches but only when plugged into your phone. * Coming up with a Rube Goldberg machine to upload patches from a web server to your CZ-5000. * thisdx7cartridgedoesnotexist.com * In a convex optimization problem, there is no gradient to descend. * Fiddling with the synthesizer sliders until you reach a corner of the parameter space that doesn't make any noise and giving up. * Camp Counselor Grant hastily drawing all the synthesizer waves on the board. * Ask any Geometer, the triangle has three sides. Love triangles are actually just two love segments. * The All Topic Fakeouts episode. * The gulf between how an artist thinks they're presenting themselves and how they're being received. * A Beautiful Rainbow of the Human Experience. * Elderly rappers with excellent flow but terrible drip. * Piling onto propaganda music. * Someone doing their own thing with confidence and authenticity. * Graffiti with immaculate copyediting. * With improved access to art tools, taste is one of the only things left to get wrong. * Only the best crappy music. * Promoting your music in r/crappymusic. * Tori the Clown Rap Gal. * The audacity of extreme autotune. * All Youtube thumbnails converging on the same cognitive attention hacks. * Singing the comments on your last video. * Situations where echo chamber amplification is fun and good for the world. * Obscure Music That Slaps. * Serbian Kolos. * The Ketron Event Chrom. * The Nightmare Klaxon that Represents Dread. * All the Fairlight CMI presets used in the Terminator 2 soundtrack. * Growing up playing samples at every possible speed in Impulse Tracker. * Slowly sucking dog food out of a can to simulate the sound of a mimetic polyalloy passing through steel bars. * It's been a long day and you're ready to go home but you need to slam 1000 more inverted glasses into bowls of yogurt, let's hurry it up guys. * That one sample library squeaking metal door sound that everyone uses. * Calling out comb filtering whenever you hear someone exhale deeply while sitting down at a desk. * The sound guy instructing all the actors when to breathe to minimize comb filtering. * Rubber Baby Knopfler Romplers. * All the things you are after you die. * The purpose of suffering. (So we can write cool poems about it.) * Making art about how trauma used to exist. * Why wireheading will not solve our problems. (Because everything uses bluetooth now.) * Who needs trauma when we have CRISPR? * Shepherding noobs. * Play Any Video Game Day. * Complicated goose controls. * Trying to play Portal as your first 3D game. * Learning video games vs. learning board games. * Trying to get into video game series that don't change. * Looking at the screen and/or ants until it coalesces into an image. * Video games filled with really gross blood squirt sounds. * Jumping on and off of buildings. * Playing Breath of the Wild and just collecting mushrooms and herbs. * Grass simulation in Breath of the Wild vs. in Horizon Zero Dawn. * Putting yourself in the head-space of the protagonist in order to do protagonist stuff. * Spelling brunch the secret way.

When Jesus said the End Times would be as the Days of Noah, one thing He was getting at is genetic tampering with the human race Pastor Gene Pensiero Find audio, video, and text of hundreds of other prophecy updates at: https://calvaryhanford.com/prophecy Read along with us at https://calvaryhanford.substack.com Follow us on YouTube at https://youtube.com/calvaryhanford — […]

Join Dr. Paloma Giangrande, Editor-in-Chief of Molecular Therapy Nucleic Acids, as she discusses a recently published MTNA article, Controlling CRISPR-Cas9 genome editing in human cells using a molecular glue degrader, with its authors Drs. Krishanu Saha and Namita Khajanchi (UW-Madison). If you enjoy this episode, check out our hybrid event this fall that will allow you to engage with pioneering researchers in gene editing! Breakthroughs in Targeted In Vivo Gene Editing will be held in San Diego and virtually November 20-21, 2025. Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

In the four years since the book’s publication, CRISPR has revolutionized the world of medical treatments and possibilities. But our world has changed drastically, too. As AI’s impact grows, U.S scientists are facing funding cuts like never before. For our final episode, we bring you a live conversation between Walter Isaacson and Jennifer Doudna at the New Orleans Book Festival. In her own words, you’ll hear Doudna explain how CRISPR blossomed from an idea to a phenomenon, and the challenges scientists faces in this politically fraught moment.See omnystudio.com/listener for privacy information.

A public murder, a public act of forgiveness, and a public reckoning with what courage really costs—this conversation starts where the news won't and moves into the places most of us live: trust, discernment, and the daily habits that shape our conscience. We open with the assassination of Charlie Kirk and the surprising witness that emerged from the memorial—clear gospel, costly grace, and a reminder that God can draw purpose from tragedy without excusing evil. The question beneath the headlines is personal: what risks will we take for truth, and how do we respond when our enemies give us every reason not to love them?From there, we move through the thickets of modern medicine, where vaccine skepticism collides with scientific claims and shifting guidance. Instead of trading slogans, we slow down to practice discernment—separating correlation from causation, weighing evidence, and remembering that loving our neighbor includes doing our homework. That same careful posture anchors a frank look at xenotransplantation, as researchers push the boundaries of pig-to-human organ transplants. We unpack somatic versus germline concerns, the special dignity of human life, and how to balance innovation, transparency, and moral guardrails when the stakes are life and death.Finally, we tackle AI's ethical drift. New studies show the more people rely on AI, the easier cheating becomes and the harder it is to think for ourselves. We share practical ways to use AI without losing integrity—designing assessments that test real understanding, cultivating intellectual friction, and resisting the algorithmic echo chambers that tell us only what we want to hear. Through it all, one thread remains: a call to rebuild the muscles of clear thinking, mercy, and courage so we can serve our neighbors and witness to Christ with honesty and hope.If this resonates, subscribe, share it with a friend, and leave a review to help others find the show. Then tell us: which topic do you want us to dig into next?SHOW NOTES:Pig Lung Xenotransplant to Human: Chinese scientists have successfully transplanted a pig lung into a human being for the first time, with the organ partially functioning before it was removed. Researchers used CRISPR technology to make six gene edits to the left lung of a pig whose organs are roughly human-sized. They transferred the lung into a brain-dead 39-year-old man. Initially, the lung delivered oxygen to his blood and removed carbon dioxide. Within 24 hours, however, signs of damage appeared, and the body began to reject the organ. Scientists ended the experiment following fluid buildup. The patient was removed from life support per his family's wishes. (Source: https://tinyurl.com/24ccpehj  accessed 8-26-25)Which Diseases Will You Have in 20 Years? Using AI Increases Unethical Behavior Support the showThe ministry of Christian Life Resources promotes the sanctity of life and reaches hearts with the Gospel. We invite you to learn more about the work we're doing: https://christianliferesources.com/

Broadcast from KSQD, Santa Cruz on 10-02-2025: Dr. Dawn opens by explaining how blood pressure treatment guidelines have been corrected back to 140/90 after the problematic 2015 SPRINT study temporarily changed recommendations to 120/80. That study used ideal measurement conditions - five minutes of quiet sitting, perfect cuff sizes, compliant patients - creating unrealistic targets that caused elderly patients to faint and break hips. The Veterans Administration and major cardiology organizations now recommend treating to 140/90, with statins only for LDL above 190 or 12% ten-year cardiovascular risk. An emailer asks about claims linking Tylenol to autism. Dr. Dawn thoroughly debunks this, explaining that Swedish studies of 2.5 million children found no association when controlling for sibling comparisons. She notes autism rates remained flat from 1960-1990 despite widespread Tylenol use, then spiked after DSM-4 in 1994 and DSM-5 in 2013 broadened diagnostic criteria. Recall bias skews studies since mothers of autistic children are asked leading questions about past Tylenol use during pregnancy when fever treatment was medically necessary. She discusses RFK Jr.'s mixed positions, comparing him to Isaac Newton who excelled at physics but believed in astrology. While criticizing vaccine misinformation, Dr. Dawn strongly supports RFK's stance on ultra-processed foods. She describes NIH researcher Kevin Hall's studies showing people consume 500 extra calories daily on ultra-processed diets versus whole foods, even when nutrients are matched. The US produces 15,000 calories per person daily, with the food industry engineered to promote overconsumption through hyper-palatable fat-sugar-salt combinations. A caller asks about Healthcare 4.0 plans for biometric tracking bracelets and digital twins. Dr. Dawn discusses privacy concerns around constant health monitoring and data collection, noting that while early disease detection could be valuable, mandatory participation raises serious civil liberties issues. She acknowledges voluntary research projects like the Million Man Study but emphasizes the importance of consent and protection against unauthorized data access by advertisers or government agencies. An emailer shares research on ultrasound brain stimulation helmets as alternatives to surgical electrode implants. Dr. Dawn explains how 256-element phased ultrasonic arrays can target brain regions like the visual cortex with high precision mechanical perturbation, potentially treating Parkinson's, Alzheimer's, and depression without surgery. The technology remains experimental, requiring MRI guidance, but could become portable and dramatically improve quality of life for neurological conditions currently requiring invasive deep brain stimulation. A caller with adrenal cancer asks about fasting-mimicking diets. Dr. Dawn explains that 14-hour fasting before chemotherapy improves outcomes because healthy cells can downshift metabolism while cancer cells cannot. Cancer cells rely only on glycolysis without mitochondrial function, making them vulnerable during fasting states. She recommends chronotherapy - scheduling treatments during fasting periods - and expresses optimism about new cancer therapies like CAR-T cells and CRISPR technologies. An emailer asks about inulin fiber for fatty liver disease. Dr. Dawn explains how this fiber found in chicory, Jerusalem artichokes, and root vegetables stimulates gut bacteria to break down fructose before it reaches the liver, preventing fructose-induced hepatic lipogenesis. Inulin supplementation protects against fatty liver disease, increases antioxidant production, and helps with obesity by reshaping the gut microbiome to better process dietary sugars.

Join Jay Gunkelman, QEEGD (the man who has analyzed over 500,000 brain scans), Dr. Mari Swingle (author of i-Minds), and host Pete Jansons for another engaging NeuroNoodle Neurofeedback Podcast episode discussing neuroscience, psychology, mental health, and brain training.✅ Autism & EEG: Jay and Dr. Mari explore autism's rise, EEG patterns, and why autism isn't “one thing” but a spectrum with genetic clusters and neurophysiological signatures.✅ Dehydration & Mental Health: How hydration, cortisol, and electrolyte balance impact EEG readings, stress, and mental performance.✅ Neurofeedback Setup Essentials: From sleep, hydration, and no gum to avoiding “wet dog” hair — the panel shares real-world stories of EEG prep gone wrong (and right).✅ Additional Topics:

2/4: HEADLINE: High-Profile Corruption and Genetic Manipulation: The Cases of Lieber and He Jiankui GUEST NAME: Brandon Weichert 50 WORD SUMMARY: Brandon Weichert details how the Thousand Talents Program corrupted US scientists like Harvard's Charles Lieber, who shared military-grade nanotech research with China. The discussion pivots to the dual-use threat of CRISPR, an American genetic tool used by He Jiankui to modify unborn twins, potentially causing unintended brain augmentations. Biohacked: China's Race to Control Life. Brandon J. Weichert  (Author) 1968 MAO AND LIN

TWiV explains experiments to create genetically modified chickens that are resistant to avian influenza infection, and discovery of combination antiviral therapy for HTLV-1 infection. Hosts: Vincent Racaniello, Alan Dove, and Rich Condit Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Creating avian influenza virus resistant chickens (Nat Comm) Antiretroviral therapy and apoptosis inhibition for HTLV-1 (Cell) HTLV-1 infection (Cleveland Clinic) Letters read on TWiV 1257 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Rich – Chagas Disease, an Endemic Disease in the United States Alan – Archive of molecular biology artifacts ends its long, strange trip at a museum Vincent – The World's Oceans Are Hurtling Toward Breaking Point Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

This week, we’re bringing you the first episode of Season 3 of the podcast ON CRISPR. Walter Isaacson — the bestselling biographer behind Musk, Einstein and Steve Jobs – and journalist Evan Ratliff (Shell Game, Mastermind, Longform) take a behind-the-scenes look at the story of Jennifer Doudna, one of the scientific pioneers behind the gene editing software, CRISPR. In this episode, Evan sits down with Walter Isaacson to discuss Doudna’s upbringing, the history of DNA’s discovery and gene editing, and Baby KJ, a CRISPR patient who represents a milestone for both researchers and patients.See omnystudio.com/listener for privacy information.

We discuss the sketchy "science by press release" of Colossal Biosciences and the controversies lurking in the history of its lead scientist. Have they resurrected dire wolves? No. Definitely not. If only overblown celebrity endorsed hype was the only problem…Did they make a Dire Wolf? (Spoiler: NOT EVEN REMOTELY CLOSE)George Church's explanation of Epstein tiesJames Arthur Ray - Guru of Death?Tony Robbins (more from Quora and Reddit)Peter Jackson and the MoaGeorge R. R. Martin and the Dire WolfFor a more… salacious take on this, check out the 2-part "Behind the Bastards" coverage of this topic. Part 1 and Part 2.--- on a more positive note ---What is CRISPR?Become a supporter of this podcast: https://www.spreaker.com/podcast/monstertalk--6267523/support.Some product links may be affiliated with Amazon revenue sharing.